JPH06234630A - Neutral metalloendopeptidase inhibitor - Google Patents
Neutral metalloendopeptidase inhibitorInfo
- Publication number
- JPH06234630A JPH06234630A JP5312366A JP31236693A JPH06234630A JP H06234630 A JPH06234630 A JP H06234630A JP 5312366 A JP5312366 A JP 5312366A JP 31236693 A JP31236693 A JP 31236693A JP H06234630 A JPH06234630 A JP H06234630A
- Authority
- JP
- Japan
- Prior art keywords
- group
- phenyl
- lower alkyl
- imino
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007935 neutral effect Effects 0.000 title claims abstract description 26
- 239000003475 metalloproteinase inhibitor Substances 0.000 title claims description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 36
- -1 (substituted)imino Chemical group 0.000 claims abstract description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 30
- 125000001841 imino group Chemical group [H]N=* 0.000 claims abstract description 23
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 206010019280 Heart failures Diseases 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011593 sulfur Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 102000003843 Metalloendopeptidases Human genes 0.000 abstract description 7
- 108090000131 Metalloendopeptidases Proteins 0.000 abstract description 7
- 125000006239 protecting group Chemical group 0.000 abstract description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007859 condensation product Substances 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 41
- 239000002904 solvent Substances 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 12
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 12
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102000003729 Neprilysin Human genes 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZNMIVJVYXWRAEN-UHFFFAOYSA-N 5-[2-(phenylmethoxycarbonylamino)ethyl]-1,3-oxazole-4-carboxylic acid Chemical compound N1=COC(CCNC(=O)OCC=2C=CC=CC=2)=C1C(=O)O ZNMIVJVYXWRAEN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- HDRLDEUNNQFUNV-UHFFFAOYSA-N benzyl 5-(2-aminoethyl)-1,3-oxazole-4-carboxylate;hydrobromide Chemical compound Br.O1C=NC(C(=O)OCC=2C=CC=CC=2)=C1CCN HDRLDEUNNQFUNV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PQVDCUSXODKCEO-UHFFFAOYSA-N methyl 5-[2-(phenylmethoxycarbonylamino)ethyl]-1,3-oxazole-4-carboxylate Chemical compound N1=COC(CCNC(=O)OCC=2C=CC=CC=2)=C1C(=O)OC PQVDCUSXODKCEO-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- CKJLJMFZZAWDKK-ZDUSSCGKSA-N (2s)-2-(phenylmethoxycarbonylamino)-3-thiophen-2-ylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CS1 CKJLJMFZZAWDKK-ZDUSSCGKSA-N 0.000 description 1
- TXHRNXJOJFPYJG-PMACEKPBSA-N (2s)-2-[[(2s)-1-[[4-(carboxymethyl)-1,3-thiazol-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-phenylbutanoic acid Chemical compound OC(=O)CC1=CSC(NC(=O)[C@H](CC=2C=CC=CC=2)N[C@@H](CCC=2C=CC=CC=2)C(O)=O)=N1 TXHRNXJOJFPYJG-PMACEKPBSA-N 0.000 description 1
- NFKRLTNUTLMUBN-ZEQRLZLVSA-N (2s)-2-[[(2s)-1-oxo-4-phenyl-1-phenylmethoxybutan-2-yl]amino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)N[C@@H](CCC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 NFKRLTNUTLMUBN-ZEQRLZLVSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- GEVGRLPYQJTKKS-UHFFFAOYSA-N 3-(phenylmethoxycarbonylamino)propanoic acid Chemical compound OC(=O)CCNC(=O)OCC1=CC=CC=C1 GEVGRLPYQJTKKS-UHFFFAOYSA-N 0.000 description 1
- VDTFGKXTOLAXCR-GOTSBHOMSA-N 3-[[(2s)-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]-3-phenylpropanoyl]amino]benzoic acid Chemical compound C([C@@H](C(=O)O)N[C@@H](CC=1C=CC=CC=1)C(=O)NC=1C=C(C=CC=1)C(O)=O)CC1=CC=CC=C1 VDTFGKXTOLAXCR-GOTSBHOMSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- IRDBFWOVMVYOML-UHFFFAOYSA-N 5-[2-(phenylmethoxycarbonylamino)ethyl]-1,3-thiazole-4-carboxylic acid Chemical compound N1=CSC(CCNC(=O)OCC=2C=CC=CC=2)=C1C(=O)O IRDBFWOVMVYOML-UHFFFAOYSA-N 0.000 description 1
- NVEQUHJGCSMFKP-ROUUACIJSA-N 5-[2-[[(2S)-2-[[(1S)-1-carboxy-3-thiophen-2-ylpropyl]amino]-3-phenylpropanoyl]amino]ethyl]-1,3-oxazole-4-carboxylic acid Chemical compound C([C@@H](C(=O)O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCCC1=C(N=CO1)C(O)=O)CC1=CC=CS1 NVEQUHJGCSMFKP-ROUUACIJSA-N 0.000 description 1
- LHAFFXWBXQIWKK-VXKWHMMOSA-N 5-[2-[[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-3-phenylpropanoyl]amino]ethyl]-1,3-thiazole-4-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](CC=1C=CC=CC=1)C(=O)NCCC1=C(N=CS1)C(O)=O)CC1=CC=CC=C1 LHAFFXWBXQIWKK-VXKWHMMOSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CPVMIPGVNZQIRU-UHFFFAOYSA-N C=1C=CC=CC=1CC=CC(=O)OCC1=CC=CC=C1 Chemical compound C=1C=CC=CC=1CC=CC(=O)OCC1=CC=CC=C1 CPVMIPGVNZQIRU-UHFFFAOYSA-N 0.000 description 1
- QQCGZYVGZBARKV-UHFFFAOYSA-N COC(C(CCC)(NC=O)NC(=O)OCC1=CC=CC=C1)=O Chemical compound COC(C(CCC)(NC=O)NC(=O)OCC1=CC=CC=C1)=O QQCGZYVGZBARKV-UHFFFAOYSA-N 0.000 description 1
- 206010007522 Cardiac asthma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010057615 Endocrine hypertension Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- NFKRLTNUTLMUBN-RPWUZVMVSA-N OC([C@H](CC1=CC=CC=C1)N[C@H](CCC1=CC=CC=C1)C(OCC1=CC=CC=C1)=O)=O Chemical compound OC([C@H](CC1=CC=CC=C1)N[C@H](CCC1=CC=CC=C1)C(OCC1=CC=CC=C1)=O)=O NFKRLTNUTLMUBN-RPWUZVMVSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JXTZSCFOQCXCLI-SVBPBHIXSA-N benzyl (2s)-2-[[(2s)-1-[(2-methylpropan-2-yl)oxy]-1-oxo-3-phenylpropan-2-yl]amino]-4-phenylbutanoate Chemical compound C([C@@H](C(=O)OC(C)(C)C)N[C@@H](CCC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 JXTZSCFOQCXCLI-SVBPBHIXSA-N 0.000 description 1
- KZYQOUJOXGXBTQ-HEVIKAOCSA-N benzyl (2s)-2-[[(2s)-1-oxo-1-[[4-(2-oxo-2-phenylmethoxyethyl)-1,3-thiazol-2-yl]amino]-3-phenylpropan-2-yl]amino]-4-phenylbutanoate Chemical compound C([C@@H](C(=O)NC=1SC=C(N=1)CC(=O)OCC=1C=CC=CC=1)N[C@@H](CCC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 KZYQOUJOXGXBTQ-HEVIKAOCSA-N 0.000 description 1
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 1
- PPBLVLQQJIWDEG-VWLOTQADSA-N benzyl 2-[2-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]-1,3-thiazol-4-yl]acetate Chemical compound C([C@@H](C(=O)NC=1SC=C(N=1)CC(=O)OCC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 PPBLVLQQJIWDEG-VWLOTQADSA-N 0.000 description 1
- GVYYJESAOCUSBX-UHFFFAOYSA-N benzyl 2-bromo-4-phenylbutanoate Chemical compound C=1C=CC=CC=1COC(=O)C(Br)CCC1=CC=CC=C1 GVYYJESAOCUSBX-UHFFFAOYSA-N 0.000 description 1
- IHTWAYPZXJSRDS-NDEPHWFRSA-N benzyl 3-[[(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]benzoate Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NC2=CC=CC(=C2)C(=O)OCC3=CC=CC=C3)NC(=O)OCC4=CC=CC=C4 IHTWAYPZXJSRDS-NDEPHWFRSA-N 0.000 description 1
- BQSQBZDSLOCNTC-BCRBLDSWSA-N benzyl 3-[[(2s)-2-[[(2s)-1-oxo-4-phenyl-1-phenylmethoxybutan-2-yl]amino]-3-phenylpropanoyl]amino]benzoate Chemical compound O=C([C@H](CC=1C=CC=CC=1)N[C@@H](CCC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)NC(C=1)=CC=CC=1C(=O)OCC1=CC=CC=C1 BQSQBZDSLOCNTC-BCRBLDSWSA-N 0.000 description 1
- CNUZXGDIRMXKJV-UHFFFAOYSA-N benzyl 4-phenylbutanoate Chemical compound C=1C=CC=CC=1COC(=O)CCCC1=CC=CC=C1 CNUZXGDIRMXKJV-UHFFFAOYSA-N 0.000 description 1
- CRPRZVWAJYPEBX-UHFFFAOYSA-N benzyl 5-(3-aminopropyl)-1,3-oxazole-4-carboxylate;hydrobromide Chemical compound Br.O1C=NC(C(=O)OCC=2C=CC=CC=2)=C1CCCN CRPRZVWAJYPEBX-UHFFFAOYSA-N 0.000 description 1
- LOGNEUMSGXYTNH-ACHIHNKUSA-N benzyl 5-[2-[[(2s)-2-[[(2s)-1-oxo-1-phenylmethoxy-4-thiophen-2-ylbutan-2-yl]amino]-3-phenylpropanoyl]amino]ethyl]-1,3-oxazole-4-carboxylate Chemical compound O=C([C@H](CC=1C=CC=CC=1)N[C@@H](CCC=1SC=CC=1)C(=O)OCC=1C=CC=CC=1)NCCC=1OC=NC=1C(=O)OCC1=CC=CC=C1 LOGNEUMSGXYTNH-ACHIHNKUSA-N 0.000 description 1
- UIJZCBGSPDKUPV-ACHIHNKUSA-N benzyl 5-[2-[[(2s)-2-[[(2s)-1-oxo-4-phenyl-1-phenylmethoxybutan-2-yl]amino]-3-thiophen-2-ylpropanoyl]amino]ethyl]-1,3-oxazole-4-carboxylate Chemical compound O=C([C@H](CC=1SC=CC=1)N[C@@H](CCC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)NCCC=1OC=NC=1C(=O)OCC1=CC=CC=C1 UIJZCBGSPDKUPV-ACHIHNKUSA-N 0.000 description 1
- KQBNCCAVKXYWNB-VWLOTQADSA-N benzyl 5-[2-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]ethyl]-1,3-oxazole-4-carboxylate Chemical compound C([C@H](NC(=O)OCC=1C=CC=CC=1)C(=O)NCCC1=C(N=CO1)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 KQBNCCAVKXYWNB-VWLOTQADSA-N 0.000 description 1
- HYZGHUYFNWVESJ-UHFFFAOYSA-N benzyl 5-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-1,3-oxazole-4-carboxylate Chemical compound CC(C)(C)OC(=O)NCCCC1=C(N=CO1)C(=O)OCC2=CC=CC=C2 HYZGHUYFNWVESJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- BJDVNAOZYCERBB-UHFFFAOYSA-N ethyl 5-[2-(phenylmethoxycarbonylamino)ethyl]-1,3-oxazole-4-carboxylate Chemical compound N1=COC(CCNC(=O)OCC=2C=CC=CC=2)=C1C(=O)OCC BJDVNAOZYCERBB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- RHMQNXNXUZLEIY-UHFFFAOYSA-N methanol;2-propan-2-yloxypropane Chemical compound OC.CC(C)OC(C)C RHMQNXNXUZLEIY-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- CRXFROMHHBMNAB-UHFFFAOYSA-N methyl 2-isocyanoacetate Chemical compound COC(=O)C[N+]#[C-] CRXFROMHHBMNAB-UHFFFAOYSA-N 0.000 description 1
- HLNWNMQKSMZDNM-UHFFFAOYSA-N methyl 5-(2-aminoethyl)-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C=1N=COC=1CCN HLNWNMQKSMZDNM-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QOISWWBTZMFUEL-NSHDSACASA-N tert-butyl (2s)-2-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@@H](N)CC1=CC=CC=C1 QOISWWBTZMFUEL-NSHDSACASA-N 0.000 description 1
- BHSPVXFPTPLEEQ-UHFFFAOYSA-N tert-butyl 3-phenyl-2-sulfanylpropanoate Chemical compound CC(C)(C)OC(=O)C(S)CC1=CC=CC=C1 BHSPVXFPTPLEEQ-UHFFFAOYSA-N 0.000 description 1
- ZOJRGDRNISZTQS-UHFFFAOYSA-N tert-butyl 3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)CCC1=CC=CC=C1 ZOJRGDRNISZTQS-UHFFFAOYSA-N 0.000 description 1
- YJNQZABOFGWOEF-UHFFFAOYSA-N tert-butyl 5-[2-(phenylmethoxycarbonylamino)ethyl]-1,3-oxazole-4-carboxylate Chemical compound N1=COC(CCNC(=O)OCC=2C=CC=CC=2)=C1C(=O)OC(C)(C)C YJNQZABOFGWOEF-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は中性メタロエンドペプチ
ダーゼ阻害剤に関する。FIELD OF THE INVENTION The present invention relates to a neutral metalloendopeptidase inhibitor.
【0002】[0002]
【従来の技術】心臓から分泌されて強力な利尿作用、ナ
トリウム利尿作用、血管拡張作用及びレニン・アンギオ
テンシン・アルドステロン系の抑制作用を有する心房性
ナトリウム利尿ペプチド(ANP)は、高血圧及び心不
全の治療に有効であることが知られている。しかしAN
P自体はポリペプチドであり、消化管での吸収が悪いた
め、投与経路は非経口に限定されている。一方、ANP
は生体内では中性メタロエンドペプチダ−ゼにより分解
されるため、この酵素阻害薬もANPの血中濃度を高
め、高血圧症及び/又は心不全の治療剤として利用しう
ることが知られている。BACKGROUND OF THE INVENTION Atrial natriuretic peptide (ANP), which is secreted from the heart and has a strong diuretic action, natriuretic action, vasodilatory action and inhibitory action on the renin-angiotensin-aldosterone system, is used for the treatment of hypertension and heart failure. It is known to be effective. But AN
Since P itself is a polypeptide and its absorption in the digestive tract is poor, the route of administration is limited to parenteral. On the other hand, ANP
Is decomposed in vivo by neutral metalloendopeptidase, and it is known that this enzyme inhibitor also increases the blood concentration of ANP and can be used as a therapeutic agent for hypertension and / or heart failure. .
【0003】[0003]
【発明が解決しようとする課題】本発明は、新規ジカル
ボン酸誘導体を有効成分としてなる中性メタロエンドペ
プチダーゼ阻害剤を提供するものである。DISCLOSURE OF THE INVENTION The present invention provides a neutral metalloendopeptidase inhibitor containing a novel dicarboxylic acid derivative as an active ingredient.
【0004】[0004]
【課題を解決するための手段】本発明は一般式〔I〕The present invention has the general formula [I]
【0005】[0005]
【化2】 [Chemical 2]
【0006】〔但し、Rは水素原子、低級アルキル基、
フェニル基又は水酸基、R1 は炭素数1〜10の直鎖又
は分枝鎖アルキル基、又はアリール基、含硫もしくは含
窒素複素単環式基及び炭素数4〜8のシクロアルキル基
から選ばれる基で置換された低級アルキル基、R2 は置
換基を有していてもよいアリール基、炭素数4〜8のシ
クロアルキル基又は含硫もしくは含窒素複素環式基、X
は硫黄原子、酸素原子、又は置換基を有していてもよい
イミノ基、Y1 及びY2 はY1 がイミノ基、酸素原子又
は硫黄原子でありY2 が窒素原子であるか、又はY1 が
ビニレン基でありY2 が基:−CH=、mは0〜3、n
は0又は1を表す。〕で示されるジカルボン酸誘導体、
そのエステル又はそれらの薬理的に許容しうる塩を有効
成分としてなる中性メタロエンドペプチダーゼ阻害剤に
関する。[Wherein R is a hydrogen atom, a lower alkyl group,
Phenyl group or hydroxyl group, R 1 is selected from linear or branched alkyl group having 1 to 10 carbon atoms, or aryl group, sulfur-containing or nitrogen-containing heteromonocyclic group, and cycloalkyl group having 4 to 8 carbon atoms A lower alkyl group substituted with a group, R 2 is an aryl group which may have a substituent, a cycloalkyl group having 4 to 8 carbon atoms, or a sulfur-containing or nitrogen-containing heterocyclic group, X
Is a sulfur atom, an oxygen atom, or an optionally substituted imino group, Y 1 and Y 2 are Y 1 being an imino group, an oxygen atom or a sulfur atom, and Y 2 is a nitrogen atom, or Y 1 is a vinylene group and Y 2 is a group: -CH =, m is 0 to 3, n
Represents 0 or 1. ] A dicarboxylic acid derivative represented by
The present invention relates to a neutral metalloendopeptidase inhibitor containing the ester or a pharmacologically acceptable salt thereof as an active ingredient.
【0007】本発明の有効成分であるジカルボン酸誘導
体〔I〕、そのエステル及びそれらの薬理的に許容しう
る塩は、優れた中性メタロエンドペプチダーゼ阻害作用
を有し、その心房性ナトリウム利尿ペプチド(ANP)
の分解抑制効果にもとづき優れた利尿作用、Na***促
進作用、血管拡張作用、レニン分泌抑制作用、アルドス
テロン分泌抑制作用等を示す。The dicarboxylic acid derivative [I], its ester and the pharmacologically acceptable salt thereof, which are the active ingredients of the present invention, have an excellent neutral metalloendopeptidase inhibitory action, and their atrial natriuretic peptide. (ANP)
It exhibits excellent diuretic action, Na excretion promoting action, vasodilatory action, renin secretion inhibiting action, aldosterone secretion inhibiting action and the like based on its decomposition inhibiting effect.
【0008】また、本発明の有効成分は、優れた降圧作
用を示すとともに、心筋肥大の抑制・改善効果をも有
し、心筋肥大による心筋収縮力の低下を防止・改善する
ことができる。このため、本発明の有効成分は降圧剤、
利尿剤あるいは、心不全や腎機能不全の予防・治療剤と
して有用である。Further, the active ingredient of the present invention has an excellent antihypertensive action and also has an effect of suppressing / improving myocardial hypertrophy, and can prevent / improve a decrease in myocardial contraction force due to myocardial hypertrophy. Therefore, the active ingredient of the present invention is an antihypertensive agent,
It is useful as a diuretic or a preventive / therapeutic agent for heart failure and renal insufficiency.
【0009】本発明の有効成分であるジカルボン酸誘導
体〔I〕の具体例としては、R1 が炭素数1〜10の直
鎖又は分枝鎖アルキル基、フェニル基置換低級アルキル
基、チエニル基置換低級アルキル基又はシクロヘキシル
基置換低級アルキル基、R2がフェニル基、低級アルコ
キシ基置換フェニル基、シクロヘキシル基、チエニル基
又はインドリル基、Xが硫黄原子、イミノ基又は低級ア
ルキル基置換イミノ基である化合物があげられる。Specific examples of the dicarboxylic acid derivative [I] which is the active ingredient of the present invention include R 1 having a linear or branched alkyl group having 1 to 10 carbon atoms, a phenyl group-substituted lower alkyl group and a thienyl group-substituted group. Compounds in which a lower alkyl group or a cyclohexyl group-substituted lower alkyl group, R 2 is a phenyl group, a lower alkoxy group-substituted phenyl group, a cyclohexyl group, a thienyl group or an indolyl group, and X is a sulfur atom, an imino group or a lower alkyl group-substituted imino group Can be given.
【0010】これらのうち薬効上好ましい化合物として
は、R1 が炭素数1〜10の直鎖又は分枝鎖アルキル
基、フェニル基置換低級アルキル基又はチエニル基置換
低級アルキル基、R2 がフェニル基又は低級アルコキシ
基置換フェニル基、Xがイミノ基又は低級アルキル基置
換イミノ基、Y1 がイミノ基、酸素原子又は硫黄原子、
Y2 が窒素原子、mが2、nが0である化合物があげら
れ、更に好ましい化合物としては、Rが水素原子、R1
が炭素数1〜10の直鎖又は分枝鎖アルキル基又はフェ
ニル基置換低級アルキル基、R2 がフェニル基、Xがイ
ミノ基、Y1 が酸素原子又は硫黄原子、Y2 が窒素原
子、mが2、nが0である化合物があげられる。Of these, preferred compounds in view of their medicinal effects are as follows: R 1 is a linear or branched alkyl group having 1 to 10 carbon atoms, a phenyl group-substituted lower alkyl group or a thienyl group-substituted lower alkyl group, and R 2 is a phenyl group. Or a phenyl group substituted with a lower alkoxy group, X is an imino group or an imino group substituted with a lower alkyl group, Y 1 is an imino group, an oxygen atom or a sulfur atom,
Examples thereof include compounds in which Y 2 is a nitrogen atom, m is 2 and n is 0, and more preferable compounds are R is a hydrogen atom and R 1
Is a linear or branched alkyl group having 1 to 10 carbon atoms or a phenyl group-substituted lower alkyl group, R 2 is a phenyl group, X is an imino group, Y 1 is an oxygen atom or a sulfur atom, Y 2 is a nitrogen atom, m 2 and n is 0.
【0011】また、他の好ましい化合物としては、Rが
水素原子、R1 がn−オクチル基又はフェニルエチル
基、R2 がフェニル基、Xがイミノ基、Y1 が酸素原子
又は硫黄原子、Y2 が窒素原子、mが2、nが0である
化合物があげられる。Further, as other preferable compounds, R is a hydrogen atom, R 1 is an n-octyl group or a phenylethyl group, R 2 is a phenyl group, X is an imino group, Y 1 is an oxygen atom or a sulfur atom, and Y is Y. An example is a compound in which 2 is a nitrogen atom, m is 2 and n is 0.
【0012】本発明の有効成分であるジカルボン酸誘導
体〔I〕は、遊離カルボン酸が優れた薬理活性を有し、
一方そのエステルは、生体内で代謝を受け、遊離のカル
ボン酸に加水分解されて活性を発揮するプロ・ドラッグ
となるものである。このため、かかるエステル残基は、
生体内で加水分解された際、薬効発現に関与せず、薬理
的に許容しうるものであれば、いずれも用いることがで
きる。エステル化合物の具体例としては、例えば、モノ
C1-8 アルキルエステル、ジC1-8 アルキルエステル、
モノ(フェニル低級アルキル)エステル、ジ(フェニル
低級アルキル)エステル、モノC1-8 アルキル−モノ
(フェニル低級アルキル)エステル等があげられる。ま
たこのうち、好ましいエステル化合物は、モノもしくは
ジC1-8 アルキルエステル化合物であり、モノもしくは
ジエチルエステル化合物が特に好ましい。The dicarboxylic acid derivative [I], which is the active ingredient of the present invention, has a free carboxylic acid having excellent pharmacological activity,
On the other hand, the ester is metabolized in vivo and hydrolyzed into a free carboxylic acid to be a prodrug that exerts its activity. Therefore, the ester residue is
When hydrolyzed in vivo, any of those that are pharmacologically acceptable without being involved in the manifestation of drug effects can be used. Specific examples of the ester compound include, for example, mono C 1-8 alkyl ester, di C 1-8 alkyl ester,
Examples thereof include mono (phenyl lower alkyl) ester, di (phenyl lower alkyl) ester, mono C 1-8 alkyl-mono (phenyl lower alkyl) ester and the like. Of these, preferred ester compounds are mono- or di-C 1-8 alkyl ester compounds, and mono- or diethyl ester compounds are particularly preferred.
【0013】また、ジカルボン酸誘導体〔I〕又はその
エステルは、その薬理的に許容しうる塩の形でも本発明
の目的に用いることができる。このような塩としては、
例えば、臭酸塩、塩酸塩、硫酸塩、リン酸塩、硝酸塩等
の無機酸付加塩、メタンスルホン酸塩、p−トルエンス
ルホン酸塩、シュウ酸塩、フマル酸塩、マレイン酸塩、
酒石酸塩、クエン酸塩等の有機付加塩をあげることがで
きる。The dicarboxylic acid derivative [I] or its ester can be used for the purpose of the present invention in the form of its pharmacologically acceptable salt. As such salt,
For example, inorganic acid addition salts such as hydrobromide, hydrochloride, sulfate, phosphate, nitrate, methanesulfonate, p-toluenesulfonate, oxalate, fumarate, maleate,
Examples thereof include organic addition salts such as tartrate and citrate.
【0014】更に、ジカルボン酸誘導体〔I〕は、2個
の不斉炭素原子にもとづく4種の光学活性体及びその混
合物のいずれをも包含し、そのうち、2個の不斉炭素原
子が共にS配置をとるもの〔以下(S−S)体と称す
る〕が薬効上とりわけ好ましい。Further, the dicarboxylic acid derivative [I] includes any of four types of optically active compounds based on two asymmetric carbon atoms and a mixture thereof, in which two asymmetric carbon atoms are both S. Those having a configuration [hereinafter referred to as (S-S) form] are particularly preferable in terms of efficacy.
【0015】またジカルボン酸誘導体〔I〕に於いて、
低級アルキル基及び低級アルコキシ基とは炭素数1〜6
のアルキル基及び炭素数1〜6のアルコキシ基を意味す
る。In the dicarboxylic acid derivative [I],
The lower alkyl group and the lower alkoxy group have 1 to 6 carbon atoms.
Means an alkyl group and an alkoxy group having 1 to 6 carbon atoms.
【0016】本発明の有効成分であるジカルボン酸誘導
体〔I〕、そのエステル又はそれらの塩の投与量は、投
与方法、患者の年令、体重、状態及び治療すべき疾患の
種類によっても異なるが、通常一日当り約1〜100m
g/kg、とりわけ3〜30mg/kg程度とするのが
好ましい。The dose of the dicarboxylic acid derivative [I], its ester or salts thereof, which is the active ingredient of the present invention, varies depending on the administration method, age of the patient, body weight, condition and kind of disease to be treated. , Usually about 1-100m per day
It is preferably g / kg, especially about 3 to 30 mg / kg.
【0017】本発明の中性メタロエンドペプチダーゼ阻
害剤は、経口的にも非経口的(例えば、静脈内、筋肉
内、皮下)にも投与することができる。The neutral metalloendopeptidase inhibitor of the present invention can be administered orally or parenterally (eg, intravenous, intramuscular, subcutaneous).
【0018】経口投与する場合の剤形は、錠剤、顆粒
剤、カプセル剤、散剤の如き固形製剤であってもよく、
溶液、懸濁液、乳液の如き液体製剤であってもよく、経
口投与に適した医薬担体と共に医薬製剤として使用する
ことができる。かかる医薬担体としては、例えば、結合
剤(シロップ、アラビアゴム、ゼラチン、ソルビット、
トラガント、ポリビニルピロリドン等)、賦形剤(乳
糖、砂糖、コーンスターチ、リン酸カリウム、ソルビッ
ト、グリシン等)、滑沢剤(ステアリン酸マグネシウ
ム、タルク、ポリエチレングリコール、シリカ等)、崩
壊剤(バレイショデンプン等)又は湿潤剤(ラウリル硫
酸ナトリウム等)等慣用なものをいずれも使用できる。The dosage form for oral administration may be solid preparations such as tablets, granules, capsules and powders,
It may be a liquid preparation such as a solution, suspension or emulsion, and can be used as a pharmaceutical preparation together with a pharmaceutical carrier suitable for oral administration. Examples of such pharmaceutical carriers include binders (syrup, gum arabic, gelatin, sorbit,
Tragant, polyvinylpyrrolidone, etc.), excipients (lactose, sugar, corn starch, potassium phosphate, sorbit, glycine, etc.), lubricants (magnesium stearate, talc, polyethylene glycol, silica, etc.), disintegrants (potato starch, etc.) ) Or a wetting agent (sodium lauryl sulfate, etc.) or any other conventional one can be used.
【0019】一方、非経口投与する場合の剤形は、例え
ば、注射用蒸留水、生理的食塩水、ブドウ糖水溶液等を
用いて注射剤や点滴注射剤とするのが好ましい。On the other hand, the dosage form for parenteral administration is preferably an injection or drip injection using, for example, distilled water for injection, physiological saline, an aqueous glucose solution or the like.
【0020】本発明の有効成分であるジカルボン酸誘導
体〔I〕は、(1)一般式〔II〕The dicarboxylic acid derivative [I], which is the active ingredient of the present invention, comprises (1) the general formula [II]
【0021】[0021]
【化3】 [Chemical 3]
【0022】〔但し、R3 はカルボキシル基の保護基,
X1 は硫黄原子、酸素原子又は置換基を有していてもよ
いイミノ基を表し、R1 、及びR2 は前記と同一意味を
有する。〕で示されるカルボン酸化合物又はその塩(例
えば、アルカリ金属塩、アルカリ土類金属塩)と一般式
〔III〕[Wherein R 3 is a protecting group for a carboxyl group,
X 1 represents a sulfur atom, an oxygen atom or an imino group which may have a substituent, and R 1 and R 2 have the same meaning as described above. ] The carboxylic acid compound or its salt (for example, alkali metal salt, alkaline earth metal salt) shown by these, and general formula [III]
【0023】[0023]
【化4】 [Chemical 4]
【0024】〔但し、R4 はカルボキシル基の保護基を
表し、R、Y1 、Y2 、m及びnは前記と同一意味を有
する。〕で示されるアミン化合物又はその塩(例えば、
鉱酸塩)とを、ペプチド合成の常法に従い、脱水剤(例
えば、1−エチル−3−(3−ジメチルアミノプロピ
ル)カルボジイミド)の存在下、縮合反応させるか、又
は化合物〔II〕のカルボキシル基における反応性誘導
体(例えば、酸ハライド、活性エステル、混酸無水物
等)とアミン化合物〔III〕とを脱酸剤(例えば、ト
リ低級アルキルアミン、水酸化アルカリ金属等)の存在
下又は非存在下で縮合反応させるか、或いは(2)一般
式〔IV〕[Wherein R 4 represents a protecting group for a carboxyl group, and R, Y 1 , Y 2 , m and n have the same meanings as described above. ] The amine compound shown by these or its salt (for example,
Mineral acid salt) is subjected to a condensation reaction in the presence of a dehydrating agent (for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) or a carboxyl group of compound [II] according to a conventional method for peptide synthesis. The reactive derivative in the group (eg, acid halide, active ester, mixed acid anhydride, etc.) and amine compound [III] in the presence or absence of a deoxidizing agent (eg, tri-lower alkylamine, alkali metal hydroxide, etc.) Or conduct the condensation reaction below, or (2) the general formula [IV]
【0025】[0025]
【化5】 [Chemical 5]
【0026】〔但し、Z1 は反応性残基を表し、他の記
号は前記と同一意味を有する。〕で示される酢酸化合物
と一般式〔V〕[Wherein Z 1 represents a reactive residue, and other symbols have the same meanings as described above. ] And an acetic acid compound represented by the general formula [V]
【0027】[0027]
【化6】 [Chemical 6]
【0028】〔但し、X2 はチオール基、水酸基、又は
置換基を有していてもよいアミノ基を表し、他の記号は
前記と同一意味を有する。〕で示される化合物又はその
塩(例えば、鉱酸塩)とを脱酸剤(例えば、トリ低級ア
ルキルアミン、水酸化アルカリ金属)の存在下又は非存
在下で縮合反応させた後、(3)X1 が非置換イミノ基
又はX2 が非置換アミノ基の場合は、所望により該生成
物を、例えば低級アルキルハライドと反応させて低級ア
ルキル化し、(4)更に所望により保護基R3 及び/又
はR4 を該保護基の種類に応じて、例えば、接触還元、
酸加水分解等の常法により除去して製造することができ
る。[However, X 2 represents a thiol group, a hydroxyl group, or an amino group which may have a substituent, and other symbols have the same meanings as described above. ] The compound represented by or a salt thereof (for example, a mineral acid salt) is subjected to a condensation reaction in the presence or absence of a deoxidizing agent (for example, tri-lower alkylamine, alkali metal hydroxide), and then (3) When X 1 is an unsubstituted imino group or X 2 is an unsubstituted amino group, the product is optionally lower alkylated by reacting with, for example, a lower alkyl halide, and (4) if desired, a protecting group R 3 and / or Alternatively, R 4 is, for example, catalytically reduced, depending on the kind of the protecting group,
It can be produced by removing it by a conventional method such as acid hydrolysis.
【0029】実験例 1 〔中性メタロエンドペプチダーゼ(NEP)阻害活性〕
Malfroyらの方法〔ザ・ジャーナル・オブ・バイ
オロジカル・ケミストリー(The Journal
of Biological Chemistry)、
第259巻、第14365−14370頁、1984
年〕に準じ、雄性Wistar系ラットの腎皮質から部
分精製したNEP画分を実験に供した。Experimental Example 1 [Neutral metalloendopeptidase (NEP) inhibitory activity]
The method of Malfroy et al. [The Journal of Biological Chemistry (The Journal
of Biological Chemistry),
Volume 259, pp 14365-14370, 1984
The NEP fraction partially purified from the renal cortex of male Wistar rats was subjected to the experiment.
【0030】NEP活性の測定はSpillantin
iらの方法〔ヨーロピアン・ジャーナル・オブ・ファー
マコロジー(European Journal of
Pharmacology)、第125巻、第147
−150頁、1986年〕に準じた。すなわち酵素溶液
に合成基質サクシニル−アラニル−アラニル−フェニル
アラニル−アミドメチルクマリン(Suc−Ala−A
la−Phe−AMC)を添加し、生成されるPhe−
AMCをさらにアミノペプチダーゼで加水分解し、生じ
たAMCを定量することにより、NEP活性を測定し
た。被験化合物のNEP阻害活性は濃度阻害曲線より5
0%抑制濃度(IC50)として求めた。結果は下記第1
表に示す通りである。NEP activity was measured by Spillantin.
i et al. [European Journal of Pharmacology
Pharmacology), Volume 125, Volume 147
-150, 1986]. That is, a synthetic substrate succinyl-alanyl-alanyl-phenylalanyl-amidomethylcoumarin (Suc-Ala-A) was added to the enzyme solution.
la-Phe-AMC) is added to produce Phe-
NEP activity was measured by further hydrolyzing AMC with aminopeptidase and quantifying the resulting AMC. The NEP inhibitory activity of the test compound was 5 from the concentration inhibition curve.
It was determined as a 0% inhibitory concentration (IC 50 ). The result is the first
As shown in the table.
【0031】[0031]
【表1】 [Table 1]
【0032】実験例 2 〔外因性ANP利尿作用増強作用〕一晩絶食した雄性S
D系ラットをウレタンで麻酔して実験に供した(一群8
匹)。0.25%カルボキシメチルセルロース(CM
C)液に懸濁した被験化合物を十二指腸内投与(100
mg/kg)し、2時間後にANPを静脈内投与した。
膀胱に挿入したカテーテルより採尿し、ANP投与によ
る尿量およびNa***量の増加を求めた。なお、対照群
には0.25%CMC液を投与した。結果は下記第2表
に示す通りである。Experimental Example 2 [Enhancement of exogenous ANP diuretic action] Male S fasted overnight
D rats were anesthetized with urethane and used for the experiment (8 per group).
). 0.25% carboxymethyl cellulose (CM
C) A test compound suspended in the liquid is administered intraduodenally (100
mg / kg), and 2 hours later, ANP was intravenously administered.
Urine was collected from a catheter inserted into the bladder, and an increase in urine volume and Na excretion amount due to ANP administration was determined. The 0.25% CMC solution was administered to the control group. The results are shown in Table 2 below.
【0033】[0033]
【表2】 [Table 2]
【0034】実験例 3 〔急性降圧作用〕左腎を摘出した雄性SD系ラットに酢
酸デオキシコルチコステロン(DOCA)を混入したシ
リコン樹脂を背部皮下に埋め込み、0.5%NaCl、
KCl溶液を飲水として与えることにより作成したDO
CA食塩高血圧ラット(DOCA−HR)を実験に供し
た。Experimental Example 3 [Acute antihypertensive action] A male SD rat from which the left kidney was removed was implanted with a silicone resin containing deoxycorticosterone acetate (DOCA) under the skin of the back, and 0.5% NaCl,
DO prepared by giving KCl solution as drinking water
CA saline hypertensive rats (DOCA-HR) were subjected to the experiment.
【0035】一晩絶食したDOCA−HR(一群4−6
匹)に被験化合物を経口投与(30mg/kg)し、投
与前および2時間後の収縮期血圧を非観血法(tail
−cuff法)により測定し、変化値を求めた。なお被
験化合物は少量のツイーン80(ポリオキシエチレンソ
ルビタンモノオレート)を用いてイオン交換水に懸濁し
た。結果は下記第3表に示す通りである。DOCA-HR fasted overnight (group 4-6
The test compound was orally administered (30 mg / kg) to 2 animals and the systolic blood pressure before and 2 hours after the administration was measured by a non-invasive method (tail).
-Cuff method) to determine the change value. The test compound was suspended in ion-exchanged water using a small amount of Tween 80 (polyoxyethylene sorbitan monooleate). The results are shown in Table 3 below.
【0036】[0036]
【表3】 [Table 3]
【0037】実験例 4 〔心筋肥大抑制作用〕雄性脳卒中易発症自然発症高血圧
ラット(一群10匹)を8%食塩を含む固形飼料(高N
a食)で飼育した。被験化合物は少量のツイーン80を
用いてイオン交換水に懸濁し、1日2回、32日間経口
投与(200mg/kg/day)した。33日目に心
臓を摘出して心室重量を測定し、体重100g当たりの
重量(相対心室重量)を算出した。被験化合物には、4
−カルボキシ−5−{2−〔N−((1S)−1−エト
キシカルボニル−3−フェニルプロピル)−(L)−フ
ェニルアラニル〕アミノエチル}オキサゾールを用い
た。結果は、下記第4表に示す通りである。Experimental Example 4 [Inhibitory effect on myocardial hypertrophy] Male stroke-prone spontaneously hypertensive rats (10 per group) were treated with a solid feed containing 8% sodium chloride (high N).
(a food). The test compound was suspended in ion-exchanged water using a small amount of Tween 80 and orally administered (200 mg / kg / day) twice a day for 32 days. On the 33rd day, the heart was removed and the ventricular weight was measured, and the weight per 100 g of body weight (relative ventricular weight) was calculated. 4 for the test compound
-Carboxy-5- {2- [N-((1S) -1-ethoxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl] aminoethyl} oxazole was used. The results are as shown in Table 4 below.
【0038】[0038]
【表4】 [Table 4]
【0039】製造例1 (1)2−ブロモ−4−フェニル酪酸ベンジルエステル
33g、(L)−フェニルアラニンtert−ブチルエ
ステル22.1g、炭酸カリウム13.8g及びヘキサ
メチルホスホリックトリアミド30mlの混合物を、室
温で終夜かくはん後、酢酸エチルを加え、不溶物をろ去
する。ろ液を洗浄、乾燥後、溶媒を留去し、残査をシリ
カゲル精製して、N−((1S)−1−ベンジルオキシ
カルボニル−3−フェニルプロピル)−(L)−フェニ
ルアラニンtert−ブチルエステル16.6g及びN
−((1R)−1−ベンジルオキシカルボニル−3−フ
ェニルプロピル)−(L)−フェニルアラニンtert
−ブチルエステル9.9gをそれぞれ油状物として得
る。Production Example 1 (1) A mixture of 33 g of 2-bromo-4-phenylbutyric acid benzyl ester, 22.1 g of (L) -phenylalanine tert-butyl ester, 13.8 g of potassium carbonate and 30 ml of hexamethylphosphoric triamide was added. After stirring overnight at room temperature, ethyl acetate is added and the insoluble matter is filtered off. The filtrate was washed and dried, the solvent was distilled off, and the residue was purified by silica gel to obtain N-((1S) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanine tert-butyl ester. 16.6g and N
-((1R) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanine tert
9.9 g of butyl ester are each obtained as an oil.
【0040】(S−S)体 NMR(CDCl3)δ:1.31(s,9H)、1.7
6〜2.06(m,3H)、2.51〜2.70(m,
2H)、2.78〜2.97(m,2H)、3.30〜
3.49(m,2H)、5.10(s,2H)、7.0
7〜7.28(m,10H)、7.34(s,5H) (2)上記(S−S)体4.73g及びトリフルオロ酢
酸30mlを氷冷下で10分間、さらに室温で50分間
かくはん後、溶媒を留去する。残査に10%炭酸カリウ
ム水溶液を加えて中和し、生じる結晶をろ取して、N−
((1S)−1−ベンジルオキシカルボニル−3−フェ
ニルプロピル)−(L)−フェニルアラニン3.09g
を得る。(SS) form NMR (CDCl 3 ) δ: 1.31 (s, 9H), 1.7
6 to 2.06 (m, 3H), 2.51 to 2.70 (m,
2H), 2.78 to 2.97 (m, 2H), 3.30 to
3.49 (m, 2H), 5.10 (s, 2H), 7.0
7 to 7.28 (m, 10H), 7.34 (s, 5H) (2) 4.73 g of the (S-S) compound and 30 ml of trifluoroacetic acid under ice cooling for 10 minutes, and further at room temperature for 50 minutes. After stirring, the solvent is distilled off. The residue was neutralized with 10% aqueous potassium carbonate solution, and the resulting crystals were collected by filtration to give N-
((1S) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanine 3.09 g
To get
【0041】M.P.141〜143.5℃ (3)本品4.2g、4−ベンジルオキシカルボニル−
5−(2−アミノエチル)オキサゾール・1臭酸塩3.
27g、1−ヒドロキシベンゾトリアゾール・1水和物
1.53g、トリエチルアミン1.4ml、1−エチル
−3−(3−ジメチルアミノプロピル)カルボジイミド
・塩酸塩1.9g及びジメチルホルムアミド30mlの
混合物を、−20℃で1時間、その後室温で終夜かくは
んする。M. P. 141-143.5 ° C (3) 4.2 g of this product, 4-benzyloxycarbonyl-
5- (2-aminoethyl) oxazole monohydrobromide salt 3.
27 g, 1-hydroxybenzotriazole monohydrate 1.53 g, triethylamine 1.4 ml, a mixture of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 1.9 g and dimethylformamide 30 ml, Stir at 20 ° C. for 1 hour and then at room temperature overnight.
【0042】溶媒を留去後、残査に酢酸エチルを加え、
洗浄、乾燥後、溶媒を留去し、残査をシリカゲルカラム
クロマトグラフィ−(溶媒:クロロホルム−酢酸エチ
ル)で精製して、4−ベンジルオキシカルボニル−5−
{2−〔N−((1S)−1−ベンジルオキシカルボニ
ル−3−フェニルプロピル)−(L)−フェニルアラニ
ル〕アミノエチル}オキサゾ−ル4.52gを無色油状
物として得る。After distilling off the solvent, ethyl acetate was added to the residue,
After washing and drying, the solvent was distilled off, and the residue was purified by silica gel column chromatography (solvent: chloroform-ethyl acetate) to give 4-benzyloxycarbonyl-5-.
4.52 g of {2- [N-((1S) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl] aminoethyl} oxazole is obtained as a colorless oil.
【0043】NMR(CDCl3)δ:1.68〜1.9
7(m,2H)、2.38〜2.76(m,3H)、
2.97〜3.59(m,7H)、4.95,5.06
(ABq,2H)、5.33(s,2H)、7.02〜
7.42(m,20H)、7.67(s,1H) 製造例2〜4 (1) 対応原料化合物〔IV〕及び〔VI〕を製造例
1−(1)と同様に処理して、下記第5表記載の化合物
を得る。NMR (CDCl 3 ) δ: 1.68 to 1.9
7 (m, 2H), 2.38 to 2.76 (m, 3H),
2.97 to 3.59 (m, 7H), 4.95, 5.06
(ABq, 2H), 5.33 (s, 2H), 7.02 ~
7.42 (m, 20H), 7.67 (s, 1H) Production Examples 2 to 4 (1) The corresponding raw material compounds [IV] and [VI] are treated in the same manner as in Production Example 1- (1), The compounds listed in Table 5 below are obtained.
【0044】[0044]
【表5】 [Table 5]
【0045】(2)上記(1)で得た(S−S)配置の
生成物を製造例1−(2)と同様に処理して、下記第6
表記載の(S−S)体化合物を得る。(2) The product of the (S-S) configuration obtained in the above (1) was treated in the same manner as in Production Example 1- (2) to give the following sixth product.
The (S-S) compound shown in the table is obtained.
【0046】[0046]
【表6】 [Table 6]
【0047】(3)上記(2)で得た生成物を製造例1
−(3)と同様に処理して、下記第7表記載の(S−
S)体化合物を得る。(3) Production Example 1 using the product obtained in (2) above
-The same treatment as in (3) is performed, and (S-
S) form compound is obtained.
【0048】[0048]
【表7】 [Table 7]
【0049】製造例5〜14 対応原料化合物〔II〕及び〔III〕を製造例1−
(3)と同様に処理して、下記第8〜10表記載の(S
−S)体の目的物を得る。Production Examples 5-14 The corresponding raw material compounds [II] and [III] were produced in Production Example 1-
The same treatment as in (3) is carried out, and the (S
-S) Obtain the target object of the body.
【0050】[0050]
【表8】 [Table 8]
【0051】[0051]
【表9】 [Table 9]
【0052】[0052]
【表10】 [Table 10]
【0053】製造例15 4−ベンジルオキシカルボニル−5−{2−〔N−
((1S)−1−ベンジルオキシカルボニル−3−フェ
ニルプロピル)−(L)−フェニルアラニル〕アミノエ
チル}オキサゾール1.8gをジメチルホルムアミド5
0ml中、パラジウム−黒100mgの存在下、3気圧
で5時間接触還元を行う。触媒をろ去後、溶媒を留去
し、得られる結晶をメタノ−ルから再結晶して、4−カ
ルボキシ−5−{2−〔N−((1S)−1−カルボキ
シ−3−フェニルプロピル)−(L)−フェニルアラニ
ル〕アミノエチル}オキサゾール1.1gを得る。Production Example 15 4-Benzyloxycarbonyl-5- {2- [N-
1.8 g of ((1S) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl] aminoethyl} oxazole was added to dimethylformamide 5
Catalytic reduction is carried out in the presence of 100 mg of palladium-black in 0 ml at 3 atm for 5 hours. After removing the catalyst by filtration, the solvent was distilled off, and the obtained crystals were recrystallized from methanol to give 4-carboxy-5- {2- [N-((1S) -1-carboxy-3-phenylpropyl]. )-(L) -Phenylalanyl] aminoethyl} oxazole 1.1 g is obtained.
【0054】M.P.179〜181℃(分解) 製造例16〜22 製造例3〜6、8、9及び13で得た生成物を製造例1
5と同様に処理して、下記第11及び12表記載の(S
−S)体の目的物を得る。M. P. 179 to 181 ° C. (decomposition) Production Examples 16 to 22 Production Products 1 to 3 obtained in Production Examples 3 to 6, 8, 9 and 13
The same process as in No. 5 is carried out, and the (S
-S) Obtain the target object of the body.
【0055】[0055]
【表11】 [Table 11]
【0056】[0056]
【表12】 [Table 12]
【0057】製造例23 4−ベンジルオキシカルボニル−5−{2−〔N−
((1S)−1−エトキシカルボニル−3−フェニルプ
ロピル)−(L)−フェニルアラニル〕アミノエチル}
チアゾール2.2g及び25%臭化水素−酢酸溶液30
mlの混合物を室温で1日間かくはんする。溶媒留去
後、10%炭酸カリウム水溶液で中和し、得られる結晶
をメタノ−ル−イソプロピルエ−テル混液から再結晶し
て4−カルボキシ−5−{2−〔N−((1S)−1−
エトキシカルボニル−3−フェニルプロピル)−(L)
−フェニルアラニル〕アミノエチル}チアゾール1.2
7gを得る。Production Example 23 4-benzyloxycarbonyl-5- {2- [N-
((1S) -1-Ethoxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl] aminoethyl}
2.2 g of thiazole and 25% hydrogen bromide-acetic acid solution 30
The ml mixture is stirred at room temperature for 1 day. After distilling off the solvent, the solution was neutralized with a 10% aqueous potassium carbonate solution, and the obtained crystals were recrystallized from a mixed solution of methanol-isopropyl ether to give 4-carboxy-5- {2- [N-((1S)- 1-
Ethoxycarbonyl-3-phenylpropyl)-(L)
-Phenylalanyl] aminoethyl} thiazole 1.2
7 g are obtained.
【0058】M.P.121〜124℃ 製造例24及び25 製造例11及び14で得た生成物を製造例23と同様に
処理して、下記第13表記載の(S−S)体の目的物を
得る。M. P. 121-124 degreeC Preparative Examples 24 and 25 The products obtained in Preparative Examples 11 and 14 are treated in the same manner as in Preparative Example 23 to obtain the (SS) -form target product shown in Table 13 below.
【0059】[0059]
【表13】 [Table 13]
【0060】製造例26〜35 (1)(2R)−3−フェニル−2−p−トルエンスル
ホニルオキシ−プロピオン酸エチル5.19g、(L)
−フェニルアラニンベンジルエステル15.74g、ジ
(イソプロピル)エチルアミン2.91g及びヘキサメ
チルホスホリックトリアミド5mlの混合物を70℃で
2日間かく拌後、酢酸エチルを加える。Production Examples 26-35 (1) 5.19 g of (2R) -3-phenyl-2-p-toluenesulfonyloxy-ethyl propionate, (L)
After stirring a mixture of 15.74 g of phenylalanine benzyl ester, 2.91 g of di (isopropyl) ethylamine and 5 ml of hexamethylphosphoric triamide for 2 days at 70 ° C., ethyl acetate is added.
【0061】混合物を洗浄、乾燥後、溶媒を留去し、残
査をシリカゲルカラムクロマト(溶媒:ヘキサン−酢酸
エチル=9:1)を精製して、N−((1S)−1−エ
トキシカルボニル−2−フェニルエチル)−(L)−フ
ェニルアラニンベンジルエステル4.45gを油状物と
して得る。After washing and drying the mixture, the solvent was distilled off, and the residue was purified by silica gel column chromatography (solvent: hexane-ethyl acetate = 9: 1) to give N-((1S) -1-ethoxycarbonyl. 2-Phenylethyl)-(L) -phenylalanine benzyl ester 4.45 g is obtained as an oil.
【0062】NMR(CDCl3)δ:1.08(t,3
H)、2.95(t,4H)、3.55〜3.69
(m,2H)、3.99(q,2H)、5.01(AB
q,2H)、7.08〜7.33(m,15H) 対応原料化合物を上記と同様に処理して、下記第14表
記載の化合物を得る。NMR (CDCl 3 ) δ: 1.08 (t, 3
H), 2.95 (t, 4H), 3.55 to 3.69.
(M, 2H), 3.99 (q, 2H), 5.01 (AB
q, 2H), 7.08 to 7.33 (m, 15H) The corresponding starting material compounds are treated in the same manner as above to obtain the compounds shown in Table 14 below.
【0063】[0063]
【表14】 [Table 14]
【0064】(2)上記で得た生成物を製造例1−
(2)又は製造例15と同様に処理して、下記第15表
記載の化合物を得る。(2) Production Example 1-Production of the Product Obtained Above
(2) or treated in the same manner as in Production Example 15 to obtain the compounds shown in Table 15 below.
【0065】[0065]
【表15】 [Table 15]
【0066】(3)上記で得た生成物を製造例1−
(3)と同様に処理して、下記第16〜19表記載の化
合物を得る。(3) Production Example 1-Production of the Product Obtained Above
Treated in the same manner as (3), the compounds shown in Tables 16 to 19 below are obtained.
【0067】[0067]
【表16】 [Table 16]
【0068】[0068]
【表17】 [Table 17]
【0069】[0069]
【表18】 [Table 18]
【0070】[0070]
【表19】 [Table 19]
【0071】製造例36〜47 対応原料化合物を製造例1−(3)と同様に処理して、
下記第20〜23表記載の化合物を得る。Production Examples 36 to 47 The corresponding starting material compounds were treated in the same manner as in Production Example 1- (3),
The compounds shown in Tables 20 to 23 below are obtained.
【0072】[0072]
【表20】 [Table 20]
【0073】[0073]
【表21】 [Table 21]
【0074】[0074]
【表22】 [Table 22]
【0075】[0075]
【表23】 [Table 23]
【0076】製造例48 (1)(2S)−3−(2−チエニル)−2−(ベンジ
ルオキシカルボニルアミノ)プロピオン酸2.56g、
4−ベンジルオキシカルボニル−5−(2−アミノエチ
ル)オキサゾール・臭化水素酸塩2.39g、1−ヒド
ロキシベンゾトリアゾール・水和物1.42g及びジメ
チルホルムアミド30mlの混合物を−20℃に冷却
し、1−エチル−3−(3−ジメチルアミノプロピル)
カルボジイミド・塩酸塩1.77gを加える。10分
後、トリエチルアミン0.93gを加え、徐々に室温に
もどした後、終夜攪拌する。溶媒を留去し、残査に酢酸
エチルを加える。混合物を洗浄、乾燥後溶媒を留去し、
残査をシリカゲルカラムクロマト(溶媒:クロロホルム
−酢酸エチル=19:1)で精製して、4−ベンジルオ
キシカルボニル−5−{2−〔N−((2S)−3−
(2−チエニル)−2−(ベンジルオキシカルボニルア
ミノ)プロピオニル)アミノ〕エチル}オキサゾール
3.5gをシロップとして得る。Production Example 48 (1) 2.56 g of (2S) -3- (2-thienyl) -2- (benzyloxycarbonylamino) propionic acid,
A mixture of 2.39 g of 4-benzyloxycarbonyl-5- (2-aminoethyl) oxazole-hydrobromide, 1.42 g of 1-hydroxybenzotriazole hydrate and 30 ml of dimethylformamide was cooled to -20 ° C. , 1-ethyl-3- (3-dimethylaminopropyl)
Add 1.77 g of carbodiimide hydrochloride. After 10 minutes, 0.93 g of triethylamine was added, the temperature was gradually returned to room temperature, and the mixture was stirred overnight. The solvent is distilled off, and ethyl acetate is added to the residue. After washing and drying the mixture, the solvent is distilled off,
The residue was purified by silica gel column chromatography (solvent: chloroform-ethyl acetate = 19: 1) and 4-benzyloxycarbonyl-5- {2- [N-((2S) -3-
3.5 g of (2-thienyl) -2- (benzyloxycarbonylamino) propionyl) amino] ethyl} oxazole are obtained as a syrup.
【0077】NMR(CDCl3)δ:3.15〜3.2
8(m,4H)、3.46〜3.59(m,2H)、
4.35(m,1H)、5.09(s,2H)、5.3
1(s,3H)、6.47(brs,1H)、6.75
(m,1H)、6.83〜6.88(m,1H)、7.
09〜7.12(m,1H)、7.32〜7.42
(m,10H)、7.69(s,1H) (2)本品2.67g及び25%臭化水素−酢酸溶液2
0mlの混合物を室温で10分間攪拌後、溶媒を留去
し、残査にエチルエーテルを加えて粉末化する。NMR (CDCl 3 ) δ: 3.15 to 3.2
8 (m, 4H), 3.46 to 3.59 (m, 2H),
4.35 (m, 1H), 5.09 (s, 2H), 5.3
1 (s, 3H), 6.47 (brs, 1H), 6.75
(M, 1H), 6.83 to 6.88 (m, 1H), 7.
09 to 7.12 (m, 1H), 7.32 to 7.42
(M, 10H), 7.69 (s, 1H) (2) 2.67 g of this product and 25% hydrogen bromide-acetic acid solution 2
After stirring 0 ml of the mixture at room temperature for 10 minutes, the solvent is distilled off, and ethyl ether is added to the residue for pulverization.
【0078】得られた粉末1.67g、(1R)−1−
ベンジルオキシカルボニル−1−(p−トルエンスルホ
ニルオキシ)−3−フェニルプロパン1.67g、トリ
エチルアミン1.75ml及びヘキサメチルホスホリッ
クトリアミド20mlの混合物を75℃で終夜攪拌後、
酢酸エチルを加える。混合物を洗浄、乾燥後、溶媒を留
去し残査をシリカゲルカラムクロマト(溶媒:クロロホ
ルム−酢酸エチル=98:2)で精製し、4−ベンジル
オキシカルボニル−5−{2−〔N−((2S)−3−
(2−チエニル)−2−(N−((1S)−1−ベンジ
ルオキシカルボニル−3−フェニルプロピル)アミノ)
プロピオニル)アミノ〕エチル}オキサゾール2.1g
を得る。1.67 g of the powder obtained, (1R) -1-
After stirring a mixture of benzyloxycarbonyl-1- (p-toluenesulfonyloxy) -3-phenylpropane 1.67 g, triethylamine 1.75 ml and hexamethylphosphoric triamide 20 ml at 75 ° C. overnight,
Add ethyl acetate. After washing and drying the mixture, the solvent was distilled off and the residue was purified by silica gel column chromatography (solvent: chloroform-ethyl acetate = 98: 2) to give 4-benzyloxycarbonyl-5- {2- [N-(( 2S) -3-
(2-thienyl) -2- (N-((1S) -1-benzyloxycarbonyl-3-phenylpropyl) amino)
Propionyl) amino] ethyl} oxazole 2.1 g
To get
【0079】M.P.81〜83℃ 製造例49〜51 (1)対応原料化合物を製造例48−(1)と同様に処
理して、次の化合物を得る。M. P. 81 to 83 ° C. Production Examples 49 to 51 (1) The corresponding starting material compounds are treated in the same manner as in Production Example 48- (1) to obtain the following compounds.
【0080】49−(1):4−ベンジルオキシカルボ
ニル−5−{2−(N−ベンジルオキシカルボニル−
(L)−フェニルアラニル)アミノエチル}オキサゾー
ル M.P.148〜149℃ 50−(1):3−ベンジルオキシカルボニル−1−
{(N−ベンジルオキシカルボニル−(L)−フェニル
アラニル)アミノ}ベンゼン M.P.141〜143℃ 51−(1):4−ベンジルオキシカルボニルメチル−
2−{(N−ベンジルオキシカルボニル−(L)−フェ
ニルアラニル)アミノ}チアゾール NMR(CDCl3)δ:3.03〜3.38(m,2
H)、3.69(s,2H)、4.73〜4.89
(m,1H)、5.07〜5.09(m,2H)、5.
14(s,2H)、5.55〜5.70(m,1H)、
6.78(s,1H)、7.04〜7.41(s,1
H) (2)上記(1)で得た化合物及び対応原料化合物をそ
れぞれ製造例48−(2)と同様に処理して、次の化合
物を得る。49- (1): 4-benzyloxycarbonyl-5- {2- (N-benzyloxycarbonyl-
(L) -Phenylalanyl) aminoethyl} oxazole M.I. P. 148-149 ° C. 50- (1): 3-benzyloxycarbonyl-1-
{(N-benzyloxycarbonyl- (L) -phenylalanyl) amino} benzene M.I. P. 141-143 ° C. 51- (1): 4-benzyloxycarbonylmethyl-
2-{(N-benzyloxycarbonyl- (L) -phenylalanyl) amino} thiazole NMR (CDCl 3 ) δ: 3.03 to 3.38 (m, 2
H), 3.69 (s, 2H), 4.73 to 4.89.
(M, 1H), 5.07 to 5.09 (m, 2H), 5.
14 (s, 2H), 5.55 to 5.70 (m, 1H),
6.78 (s, 1H), 7.04 to 7.41 (s, 1
H) (2) The compound obtained in (1) above and the corresponding starting material compound are treated in the same manner as in Production Example 48- (2) to obtain the following compound.
【0081】49−(2):4−ベンジルオキシカルボ
ニル−5−{2−〔N−((1S)−1−ベンジルオキ
シカルボニル−3−(2−チエニル)プロピル)−
(L)−フェニルアラニル〕アミノエチル}オキサゾー
ル 性状:シロップ NMR(CDCl3)δ:1.66(brs,1H)、
1.50〜1.90(m,2H)、2.31〜2.39
(m,2H)、2.60(dd,1H)、3.13〜
3.33(m,5H)、3.33〜3.49(m,2
H)、5.02及び5.11(ABq,2H)、5.3
5(s,2H)、6.53(m,1H)、6.85
(m,1H)、7.08(m,1H)、7.16〜7.
52(m,16H)、7.69(s,1H) 50−(2):3−ベンジルオキシカルボニル−1−
{〔N−((1S)−1−ベンジルオキシカルボニル−
3−フェニルプロピル)−(L)−フェニルアラニル〕
アミノ}ベンゼン 性状:シロップ NMR(CDCl3)δ:1.60〜2.25(m,4
H)、2.51〜3.02(m,2H)、3.13〜
3.45(m,2H)、4.98及び5.08(AB
q,2H)、5.32及び5.41(ABq,2H)、
6.85〜7.44(m,24H)、7.70〜8.0
1(m,1H) 51−(2):4−ベンジルオキシカルボニルメチル−
2−{(N−((1S)−1−ベンジルオキシカルボニ
ル−3−フェニルプロピル)−(L)−フェニルアラニ
ル)アミノ}チアゾール 性状:シロップ NMR(CDCl3)δ:1.85〜2.06(m,2
H)、2.07〜2.28(m,2H)、2.53〜
2.76(m,2H)、2.81〜3.00(m,1
H)、3.44〜3.56(m,1H)、3.76
(s,2H)、5.15〜5.17(m,4H)、6.
80〜7.42(m,21H) 製造例52〜68 製造例26〜32、36〜39、41〜43、46〜4
7、49で得た生成物をそれぞれ製造例15と同様に処
理して、下記第24〜28表記載の化合物を得る。49- (2): 4-benzyloxycarbonyl-5- {2- [N-((1S) -1-benzyloxycarbonyl-3- (2-thienyl) propyl)-
(L) -Phenylalanyl] aminoethyl} oxazole Property: Syrup NMR (CDCl 3 ) δ: 1.66 (brs, 1H),
1.50 to 1.90 (m, 2H), 2.31 to 2.39
(M, 2H), 2.60 (dd, 1H), 3.13 ~
3.33 (m, 5H), 3.33 to 3.49 (m, 2
H), 5.02 and 5.11 (ABq, 2H), 5.3.
5 (s, 2H), 6.53 (m, 1H), 6.85
(M, 1H), 7.08 (m, 1H), 7.16 to 7.
52 (m, 16H), 7.69 (s, 1H) 50- (2): 3-benzyloxycarbonyl-1-
{[N-((1S) -1-benzyloxycarbonyl-
3-Phenylpropyl)-(L) -phenylalanyl]
Amino} benzene Property: syrup NMR (CDCl 3 ) δ: 1.60 to 2.25 (m, 4
H), 2.51 to 3.02 (m, 2H), 3.13 to
3.45 (m, 2H), 4.98 and 5.08 (AB
q, 2H), 5.32 and 5.41 (ABq, 2H),
6.85-7.44 (m, 24H), 7.70-8.0
1 (m, 1H) 51- (2): 4-benzyloxycarbonylmethyl-
2-{(N-((1S) -1-benzyloxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl) amino} thiazole Property: Syrup NMR (CDCl 3 ) δ: 1.85-2. 06 (m, 2
H), 2.07 to 2.28 (m, 2H), 2.53 to
2.76 (m, 2H), 2.81 to 3.00 (m, 1
H), 3.44 to 3.56 (m, 1H), 3.76.
(S, 2H), 5.15 to 5.17 (m, 4H), 6.
80 to 7.42 (m, 21H) Production Examples 52 to 68 Production Examples 26 to 32, 36 to 39, 41 to 43, 46 to 4
The products obtained in Nos. 7 and 49 are treated in the same manner as in Production Example 15 to obtain the compounds shown in Tables 24 to 28 below.
【0082】[0082]
【表24】 [Table 24]
【0083】[0083]
【表25】 [Table 25]
【0084】[0084]
【表26】 [Table 26]
【0085】[0085]
【表27】 [Table 27]
【0086】[0086]
【表28】 [Table 28]
【0087】製造例69 製造例1で得た化合物2.6g、ヨウ化メチル0.4m
l、炭酸カリウム0.83g及びヘキサメチルホスホリ
ックトリアミド3mlの混合物を室温で終夜攪拌後、酢
酸エチルを加える。不溶物をろ去し、ろ液を洗浄、乾燥
後、溶媒を留去する。残査をシリカゲルカラムクロマト
(溶媒:クロロホルム−酢酸エチル=95:5)で精製
して、4−ベンジルオキシカルボニル−5−{2−〔N
−((1S)−1−ベンジルオキシカルボニル−3−フ
ェニルプロピル)−N−メチル−(L)−フェニルアラ
ニル〕アミノエチル}オキサゾール1.81gを油状物
として得る。Production Example 69 2.6 g of the compound obtained in Production Example 1 and 0.4 m of methyl iodide
After stirring a mixture of 1, 1, 0.83 g of potassium carbonate and 3 ml of hexamethylphosphoric triamide overnight at room temperature, ethyl acetate is added. The insoluble matter is filtered off, the filtrate is washed and dried, and then the solvent is distilled off. The residue was purified by silica gel column chromatography (solvent: chloroform-ethyl acetate = 95: 5), and 4-benzyloxycarbonyl-5- {2- [N
1.81 g of-((1S) -1-benzyloxycarbonyl-3-phenylpropyl) -N-methyl- (L) -phenylalanyl] aminoethyl} oxazole are obtained as an oil.
【0088】NMR(CDCl3)δ:1.65(s,1
H)、1.65〜1.97(m,2H)、2.35
(s,3H)、2.35〜2.54(m,2H)、2.
65〜2.82(m,1H)、3.00〜3.56
(m,7H)、4.92〜5.17(m,2H)、5.
32(s,2H)、6.99〜7.43(m,20
H)、7.65(s,1H) 製造例70〜71 製造例50及び69で得た化合物を製造例15と同様に
処理して、次の化合物を得る。NMR (CDCl 3 ) δ: 1.65 (s, 1
H), 1.65 to 1.97 (m, 2H), 2.35.
(S, 3H), 2.35 to 2.54 (m, 2H), 2.
65-2.82 (m, 1H), 3.00-3.56
(M, 7H), 4.92 to 5.17 (m, 2H), 5.
32 (s, 2H), 6.99 to 7.43 (m, 20)
H), 7.65 (s, 1H) Production Examples 70 to 71 The compounds obtained in Production Examples 50 and 69 are treated in the same manner as in Production Example 15 to obtain the following compounds.
【0089】70:3−カルボキシ−1−{〔N−
((1S)−1−カルボキシ−3−フェニルプロピル)
−(L)−フェニルアラニル〕アミノ}ベンゼンを得
る。70: 3-carboxy-1-{[N-
((1S) -1-carboxy-3-phenylpropyl)
-(L) -phenylalanyl] amino} benzene is obtained.
【0090】M.P.201〜202℃(分解) 71:4−カルボキシ−5−{2−(N−((1S)−
1−カルボキシ−3−フェニルプロピル)−N−メチル
−(L)−フェニルアラニル〕アミノエチル}オキサゾ
ール M.P.104〜106℃ 製造例72〜73 製造例49及び51で得た化合物を製造例23と同様に
処理して、次の化合物を得る。M. P. 201-202 ° C. (decomposition) 71: 4-carboxy-5- {2- (N-((1S)-
1-carboxy-3-phenylpropyl) -N-methyl- (L) -phenylalanyl] aminoethyl} oxazole M.I. P. 104 to 106 ° C Production Examples 72 to 73 The compounds obtained in Production Examples 49 and 51 are treated in the same manner as in Production Example 23 to obtain the following compounds.
【0091】72:4−カルボキシ−5−{2−〔N−
((1S)−1−カルボキシ−3−(2−チエニル)プ
ロピル)−(L)−フェニルアラニル〕アミノエチル}
オキサゾール M.P.125〜127℃(分解) 73:4−カルボキシメチル−2−{〔N−((1S)
−1−カルボキシ−3−フェニルプロピル)−(L)−
フェニルアラニル〕アミノ}チアゾール M.P.178℃(分解) 製造例74 製造例35で得た化合物0.35g、2N−NaOH
0.88ml及びメタノール20mlを室温で終夜かく
拌後、混合物に水を加える。メタノールを留去し、残査
をエチルエーテル抽出後、水層を1N−HClで中和
し、酢酸エチルで抽出する。抽出液を洗浄、乾燥後、溶
媒を留去し、イソプロピルエーテルを加え、粉末化する
ことにより、4−カルボキシ−5−{2−〔N−((1
S)−1−カルボキシ−2−フェニルエチル)−(O−
メチル)−(L)−チロシル〕アミノエチル}オキサゾ
ール0.18gを得る。72: 4-carboxy-5- {2- [N-
((1S) -1-Carboxy-3- (2-thienyl) propyl)-(L) -phenylalanyl] aminoethyl}
Oxazole M. P. 125-127 ° C. (decomposition) 73: 4-carboxymethyl-2-{[N-((1S)
-1-Carboxy-3-phenylpropyl)-(L)-
Phenylalanyl] amino} thiazole M. P. 178 ° C (decomposition) Production Example 74 Compound obtained in Production Example 35 0.35 g, 2N-NaOH
After stirring 0.88 ml and 20 ml of methanol at room temperature overnight, water is added to the mixture. Methanol is distilled off, the residue is extracted with ethyl ether, the aqueous layer is neutralized with 1N-HCl, and extracted with ethyl acetate. The extract was washed and dried, the solvent was evaporated, isopropyl ether was added, and the mixture was pulverized to give 4-carboxy-5- {2- [N-((1
S) -1-carboxy-2-phenylethyl)-(O-
0.18 g of methyl)-(L) -tyrosyl] aminoethyl} oxazole is obtained.
【0092】M.P.103〜106℃ 製造例75〜80 製造例26、33〜35及び46で得た化合物を製造例
74を同様に処理して、下記第29表記載の化合物を得
る。M. P. 103 to 106 ° C Production Examples 75 to 80 The compounds obtained in Production Examples 26, 33 to 35 and 46 are treated in the same manner as in Production Example 74 to obtain the compounds shown in Table 29 below.
【0093】[0093]
【表29】 [Table 29]
【0094】製造例81 (1)1−tert−ブトキシカルボニル−2−フェニ
ルエタンチオール1.2g、水素化ナトリウム(60%
オイル)0.22g及びジメチルホルムアミド20ml
の混合物を室温で30分間攪拌後、氷冷下2−ブロモ−
4−フェニル酪酸ベンジルエステル1.7gのジメチル
ホルムアミド5ml溶液を滴下し、室温で1時間攪拌す
る。混合物にエチルエーテルを加え、洗浄後、溶媒を留
去し、残査をシリカゲルクロマト(溶媒:ヘキサン−エ
チルエーテル=95:5)で精製して、2−(1−ベン
ジルオキシカルボニル−3−フェニルプロピル)チオ−
3−フェニルプロピオン酸tert−ブチルエステル
1.25gを油状物として得る。Production Example 81 (1) 1.2 g of 1-tert-butoxycarbonyl-2-phenylethanethiol, sodium hydride (60%
Oil) 0.22 g and dimethylformamide 20 ml
The mixture was stirred at room temperature for 30 minutes, and then cooled with ice under 2-bromo-.
A solution of 4-phenylbutyric acid benzyl ester (1.7 g) in dimethylformamide (5 ml) was added dropwise, and the mixture was stirred at room temperature for 1 hour. Ethyl ether was added to the mixture, and after washing, the solvent was distilled off, and the residue was purified by silica gel chromatography (solvent: hexane-ethyl ether = 95: 5) to give 2- (1-benzyloxycarbonyl-3-phenylpropene). Le) Thio
1.25 g of 3-phenylpropionic acid tert-butyl ester are obtained as an oil.
【0095】NMR(CDCl3)δ:1.30(m,9
H)、1.96〜2.24(m,2H)、2.59〜
3.14(m,4H)、3.35〜3.66(m,2
H)、5.12(m,2H)、7.06〜7.36
(m,15H) (2)本品1.47g、アニソール1.71g及びトリ
フルオロ酢酸10mlの混合物を室温で1時間かく拌
後、溶媒を留去する。残査にトルエンを加え再び溶媒を
留去する。該操作を2回繰り返す。得られる生成物0.
86g,1−ヒドロキシベンゾトリアゾール・水和物
0.55g、1−エチル−3−(3−ジメチルアミノプ
ロピル)カルボジイミド・塩酸塩0.69g及びトリエ
チルアミン0.5mlを−20℃で混合した後、室温ま
で徐々にもどしながら終夜攪拌する。NMR (CDCl 3 ) δ: 1.30 (m, 9
H), 1.96 to 2.24 (m, 2H), 2.59 to
3.14 (m, 4H), 3.35 to 3.66 (m, 2
H), 5.12 (m, 2H), 7.06 to 7.36.
(M, 15H) (2) A mixture of 1.47 g of this product, 1.71 g of anisole and 10 ml of trifluoroacetic acid was stirred at room temperature for 1 hour, and then the solvent was distilled off. Toluene is added to the residue and the solvent is distilled off again. The operation is repeated twice. The product obtained
86 g, 1-hydroxybenzotriazole hydrate 0.55 g, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 0.69 g and triethylamine 0.5 ml were mixed at -20 ° C and then room temperature Stir overnight while gradually returning to.
【0096】溶媒を留去し、残査に酢酸エチルを加え、
洗浄、乾燥後、溶媒を留去し、残査をシリカゲルクロマ
ト(溶媒:ヘキサン−酢酸エチル=5:1)で精製し
て、4−ベンジルオキシカルボニル−5−{〔(2S)
−3−フェニル−2−(1−ベンジルオキシカルボニル
−3−フェニルプロピルチオ)プロピオニル〕アミノエ
チル}オキサゾール1.13gを油状物として得る。The solvent was distilled off, ethyl acetate was added to the residue,
After washing and drying, the solvent was distilled off, and the residue was purified by silica gel chromatography (solvent: hexane-ethyl acetate = 5: 1) to give 4-benzyloxycarbonyl-5-{[(2S).
1.13 g of -3-phenyl-2- (1-benzyloxycarbonyl-3-phenylpropylthio) propionyl] aminoethyl} oxazole is obtained as an oil.
【0097】NMR(CDCl3)δ:1.89(m,1
H)、2.12(m,1H)、2.60(m,2H)、
2.82(m,1H)、2.99〜3.52(m,7
H)、5.10(m,2H)、5.30(m,2H)、
6.93〜7.41(m,20H)、7.65(s,1
H) (3)本品1.00g、パラジウムブラック2g及びメ
タノール50mlの混合物を水素雰囲気(3気圧)下で
終夜攪拌する。触媒をろ別後、溶媒を留去して、4−カ
ルボキシ−5−{〔(2S)−3−フェニル−2−(1
−カルボキシ−3−フェニルプロピルチオ)プロピオニ
ル〕アミノエチル}オキサゾール0.69gを油状物と
して得る。NMR (CDCl 3 ) δ: 1.89 (m, 1
H), 2.12 (m, 1H), 2.60 (m, 2H),
2.82 (m, 1H), 2.99 to 3.52 (m, 7
H), 5.10 (m, 2H), 5.30 (m, 2H),
6.93 to 7.41 (m, 20H), 7.65 (s, 1
H) (3) A mixture of 1.00 g of this product, 2 g of palladium black and 50 ml of methanol is stirred overnight under a hydrogen atmosphere (3 atm). After the catalyst was filtered off, the solvent was distilled off to give 4-carboxy-5-{[(2S) -3-phenyl-2- (1
0.69 g of -carboxy-3-phenylpropylthio) propionyl] aminoethyl} oxazole is obtained as an oil.
【0098】NMR(CDCl3)δ:1.75〜1.9
8(m,2H)、2.22〜2.39(m,1H)、
2.50〜2.62(m,2H)、2.73〜2.89
(m,2H)、3.01〜3.36(m,5H)、3.
36〜3.66(m,1H)、7.15〜7.37
(m,10H)、8.25及び8.26(s,s,1
H) 〔原料化合物の調整〕 参考例1 (1)N−ベンジルオキシカルボニル−β−アラニン3
3.5g、イソシアノ酢酸メチルエステル15g、ジエ
チルホスホリルシアニド31.8g、1,8−ジアザビ
シクロ〔5,4,0〕ウンデカ−7−エン23g、トリ
エチルアミン42ml及びジメチルホルムアミド300
mlの混合物を、室温で終夜かくはんする。その後溶媒
を留去し、酢酸エチルを加え、洗浄、乾燥後、溶媒を留
去し、残査をシリカゲル精製し、イソプロピルエーテル
で結晶化後、酢酸エチル−イソプロピルエ−テル混液よ
り再結晶して、4−メトキシカルボニル−5−{2−
(ベンジルオキシカルボニルアミノ)エチル}オキサゾ
ール22.6gを得る。NMR (CDCl 3 ) δ: 1.75 to 1.9
8 (m, 2H), 2.22 to 2.39 (m, 1H),
2.50 to 2.62 (m, 2H), 2.73 to 2.89
(M, 2H), 3.01 to 3.36 (m, 5H), 3.
36-3.66 (m, 1H), 7.15-7.37
(M, 10H), 8.25 and 8.26 (s, s, 1
H) [Preparation of raw material compound] Reference Example 1 (1) N-benzyloxycarbonyl-β-alanine 3
3.5 g, methyl isocyanoacetate 15 g, diethylphosphoryl cyanide 31.8 g, 1,8-diazabicyclo [5,4,0] undec-7-ene 23 g, triethylamine 42 ml and dimethylformamide 300.
The ml mixture is stirred overnight at room temperature. After that, the solvent was distilled off, ethyl acetate was added, and after washing and drying, the solvent was distilled off, the residue was purified with silica gel, crystallized with isopropyl ether, and recrystallized from an ethyl acetate-isopropyl ether mixed liquid. , 4-methoxycarbonyl-5- {2-
22.6 g of (benzyloxycarbonylamino) ethyl} oxazole are obtained.
【0099】M.P.68〜70℃ (2)本品5g及び25%臭化水素−酢酸溶液50ml
を室温で15分間かくはんし、その後溶媒を留去する。
残査をジエチルエ−テルで結晶化して、4−メトキシカ
ルボニル−5−(2−アミノエチル)オキサゾール・1
臭酸塩を粗結晶として得、精製することなく次反応に用
いる。M. P. 68-70 ° C (2) 5 g of this product and 50 ml of 25% hydrogen bromide-acetic acid solution
Is stirred for 15 minutes at room temperature and then the solvent is distilled off.
The residue was crystallized with diethyl ether to give 4-methoxycarbonyl-5- (2-aminoethyl) oxazole.
The hydrobromide salt is obtained as crude crystals and used in the next reaction without purification.
【0100】参考例2 (1) 対応原料化合物を参考例1−(1)と同様に処
理して、次の化合物を得る。Reference Example 2 (1) The corresponding starting compound was treated in the same manner as in Reference Example 1- (1) to obtain the following compound.
【0101】4−ベンジルオキシカルボニル−5−{3
−(tert−ブトキシカルボニルアミノ)プロピル}
オキサゾール M.P.124〜126℃ (2) 本品を参考例1−(2)と同様に処理して、4
−ベンジルオキシカルボニル−5−(3−アミノプロピ
ル)オキサゾール・1臭酸塩を得る。4-benzyloxycarbonyl-5- {3
-(Tert-Butoxycarbonylamino) propyl}
Oxazole M. P. 124-126 ° C (2) This product was treated in the same manner as in Reference Example 1- (2), and 4
-Benzyloxycarbonyl-5- (3-aminopropyl) oxazole monohydrobromide is obtained.
【0102】参考例3〜9 (1) 対応原料化合物を参考例1−(1)と同様に処
理して、下記第30表記載の化合物を得る。Reference Examples 3 to 9 (1) The corresponding starting material compounds are treated in the same manner as in Reference Example 1- (1) to obtain the compounds shown in Table 30 below.
【0103】[0103]
【表30】 [Table 30]
【0104】(2) (1)で得た化合物を参考例1−
(2)と同様に処理して、下記第31表記載の化合物を
得る。(2) The compound obtained in (1) was used in Reference Example 1-
Treated in the same manner as (2), the compounds shown in Table 31 below are obtained.
【0105】[0105]
【表31】 [Table 31]
【0106】参考例10 (1)4−メトキシカルボニル−5−{2−(ベンジル
オキシカルボニルアミノ)エチル}オキサゾール30
g、2N水酸化ナトリウム水溶液75ml及びメタノー
ル75mlの混合物を、室温で3時間かくはんする。メ
タノールを留去後、氷冷下1N塩酸を滴下し、得られる
結晶をろ取して、4−カルボキシ−5−{2−(ベンジ
ルオキシカルボニルアミノ)エチル}オキサゾール2
5.8gを得、精製することなく次反応に用いる。Reference Example 10 (1) 4-Methoxycarbonyl-5- {2- (benzyloxycarbonylamino) ethyl} oxazole 30
g, a mixture of 75 ml of 2N aqueous sodium hydroxide solution and 75 ml of methanol is stirred at room temperature for 3 hours. After distilling off methanol, 1N hydrochloric acid was added dropwise under ice cooling, and the obtained crystals were collected by filtration to give 4-carboxy-5- {2- (benzyloxycarbonylamino) ethyl} oxazole 2
5.8 g are obtained and used in the next reaction without purification.
【0107】(2)本品2.9g、ジシクロヘキシルア
ミン1.81g、ヨウ化エチル2.33g及びジメチル
ホルムアミド20mlの混合物を、室温で終夜かくはん
する。溶媒留去後、残査に酢酸エチル30mlを加え、
洗浄、乾燥後、溶媒を留去し、残査をシリカゲル精製
後、イソプロピルエーテルで結晶化し、酢酸エチル−n
−ヘキサン混液より再結晶して、4−エトキシカルボニ
ル−5−{2−(ベンジルオキシカルボニルアミノ)エ
チル}オキサゾール2.89gを得る。(2) A mixture of 2.9 g of this product, 1.81 g of dicyclohexylamine, 2.33 g of ethyl iodide and 20 ml of dimethylformamide is stirred overnight at room temperature. After distilling off the solvent, 30 ml of ethyl acetate was added to the residue,
After washing and drying, the solvent was distilled off, the residue was purified by silica gel and crystallized with isopropyl ether, and ethyl acetate-n
It is recrystallized from a mixed solution of hexane to obtain 2.89 g of 4-ethoxycarbonyl-5- {2- (benzyloxycarbonylamino) ethyl} oxazole.
【0108】M.P.46〜48℃ (3)本品3.18gを参考例1−(2)と同様に処理
して、4−エトキシカルボニル−5−(2−アミノエチ
ル)オキサゾール・1臭酸塩を粗結晶として得、精製す
ることなく次反応に用いる。M. P. 46-48 ° C (3) 3.18 g of this product was treated in the same manner as in Reference Example 1- (2) to give 4-ethoxycarbonyl-5- (2-aminoethyl) oxazole monohydrochloride as crude crystals. Obtained and used in the next reaction without purification.
【0109】参考例11 (1)4−メトキシカルボニル−5−{2−(ベンジル
オキシカルボニルアミノ)エチル}オキサゾール36.
5g、濃塩酸90ml及びメタノール270mlの混合
物を、55℃で6時間かくはんする。溶媒留去後、残査
をテトラヒドロフランに溶解し、トリエチルアミン21
mlで中和する。さらに溶液を0℃に冷却し、ギ酸45
0mlを加え、同温度で無水酢酸150mlを滴下す
る。10℃で3時間かくはん後、氷水を加え、溶媒留去
後、残査を酢酸エチルに溶解し、洗浄、乾燥後、溶媒を
留去し、残査をシリカゲルで精製し、3−オキソ−5−
(ベンジルオキシカルボニルアミノ)−2−(ホルミル
アミノ)ペンタン酸メチルエステル20gを無色油状物
として得る。Reference Example 11 (1) 4-methoxycarbonyl-5- {2- (benzyloxycarbonylamino) ethyl} oxazole 36.
A mixture of 5 g, 90 ml of concentrated hydrochloric acid and 270 ml of methanol is stirred at 55 ° C. for 6 hours. After the solvent was distilled off, the residue was dissolved in tetrahydrofuran and triethylamine 21
Neutralize with ml. The solution is further cooled to 0 ° C. and formic acid 45
0 ml is added and 150 ml of acetic anhydride is added dropwise at the same temperature. After stirring at 10 ° C for 3 hours, ice water was added, the solvent was distilled off, the residue was dissolved in ethyl acetate, washed and dried, the solvent was distilled off, and the residue was purified on silica gel to give 3-oxo-5. −
20 g of (benzyloxycarbonylamino) -2- (formylamino) pentanoic acid methyl ester are obtained as a colorless oil.
【0110】NMR(CDCl3)δ:2.86〜3.1
3(m,2H)、3.45〜3.53(m,2H)、
3.79(s,3H)、5.09(s,2H)、5.2
9(d,1H)、5.1〜5.5(br,1H)、6.
8〜7.0(m,1H)7.34(s,5H)、8.2
2(s,1H) (2)本品20g、2,4−ビス(4−メトキシフェニ
ル)−1,3−ジチア−2,4−ジホスフェタン−2,
4−ジスルフィド12.5g及びトルエン300mlの
混合物を30分間還流する。溶媒留去後、残査をシリカ
ゲルで精製後、イソプロピルエーテルで結晶化し、酢酸
エチル−イソプロピルエーテル混液より再結晶して、4
−メトキシカルボニル−5−{2−(ベンジルオキシカ
ルボニルアミノ)エチル}チアゾール10.5gを得
る。NMR (CDCl 3 ) δ: 2.86 to 3.1
3 (m, 2H), 3.45 to 3.53 (m, 2H),
3.79 (s, 3H), 5.09 (s, 2H), 5.2
9 (d, 1H), 5.1-5.5 (br, 1H), 6.
8 to 7.0 (m, 1H) 7.34 (s, 5H), 8.2
2 (s, 1H) (2) 20 g of this product, 2,4-bis (4-methoxyphenyl) -1,3-dithia-2,4-diphosphetan-2,
A mixture of 12.5 g of 4-disulfide and 300 ml of toluene is refluxed for 30 minutes. After evaporating the solvent, the residue was purified by silica gel, crystallized with isopropyl ether, and recrystallized from a mixed solution of ethyl acetate-isopropyl ether to give 4
10.5 g of -methoxycarbonyl-5- {2- (benzyloxycarbonylamino) ethyl} thiazole are obtained.
【0111】M.P.108〜110℃ (3)本品を参考例10−(1)と同様に処理して、4
−カルボキシ−5−{2−(ベンジルオキシカルボニル
アミノ)エチル}チアゾールを粗結晶として得、精製す
ることなく次反応に用いる。M. P. 108-110 ° C (3) This product was treated in the same manner as in Reference Example 10- (1), and 4
-Carboxy-5- {2- (benzyloxycarbonylamino) ethyl} thiazole is obtained as crude crystals and used in the next reaction without purification.
【0112】参考例12〜16 (1)対応化合物を参考例11−(1)〜(2)と同様
に処理して、下記第32表記載の化合物を得る。Reference Examples 12 to 16 (1) The corresponding compounds are treated in the same manner as in Reference Examples 11- (1) and (2) to obtain the compounds shown in Table 32 below.
【0113】[0113]
【表32】 [Table 32]
【0114】(2)対応化合物を参考例1−(2)と同
様に処理して、下記第33表記載の化合物を得る。(2) The corresponding compound is treated in the same manner as in Reference Example 1- (2) to obtain the compounds shown in Table 33 below.
【0115】[0115]
【表33】 [Table 33]
【0116】参考例17 (1) 対応原料化合物を参考例11−(1)と同様に
処理して、1−tert−ブトキシカルボニル−5−ベ
ンジルオキシカルボニル−4−{2−(tert−ブト
キシカルボニルアミノ)エチル}イミダゾールを得る。Reference Example 17 (1) The corresponding starting material compound was treated in the same manner as in Reference Example 11- (1) to give 1-tert-butoxycarbonyl-5-benzyloxycarbonyl-4- {2- (tert-butoxycarbonyl). Amino) ethyl} imidazole is obtained.
【0117】M.P.124〜126℃ (2) 本品を参考例1−(2)と同様に処理して、5
−ベンジルオキシカルボニル−4−{2−アミノエチ
ル}イミダゾール・2臭酸塩を得る。M. P. 124-126 ° C (2) This product was treated in the same manner as in Reference Example 1- (2), and 5
-Benzyloxycarbonyl-4- {2-aminoethyl} imidazole dihydrobromide is obtained.
【0118】参考例18 (1)4−カルボキシ−5−{2−(ベンジルオキシカ
ルボニルアミノ)エチル}オキサゾール2.9g、ピリ
ジン4.9g、tert−ブチルアルコール6ml及び
クロロホルム50mlの混合物に、−10℃でホスホリ
ルクロリド1.84gを滴下し、同温度で1時間、さら
に室温で終夜かくはんする。洗浄、乾燥後、溶媒を留去
し、残査をシリカゲル精製して、4−tert−ブトキ
シカルボニル−5−{2−(ベンジルオキシカルボニル
アミノ)エチル}オキサゾール2.85gを無色油状物
として得る。Reference Example 18 (1) -10 g of a mixture of 4-carboxy-5- {2- (benzyloxycarbonylamino) ethyl} oxazole (2.9 g), pyridine (4.9 g), tert-butyl alcohol (6 ml) and chloroform (50 ml) was used. Phosphoryl chloride (1.84 g) was added dropwise at 0 ° C, and the mixture was stirred at the same temperature for 1 hr and at room temperature overnight. After washing and drying, the solvent was distilled off and the residue was purified by silica gel to obtain 2.85 g of 4-tert-butoxycarbonyl-5- {2- (benzyloxycarbonylamino) ethyl} oxazole as a colorless oil.
【0119】NMR(CDCl3)δ:1.58(s,9
H)、3.22〜3.28(m,2H)、3.50〜
3.59(m,2H)、5.08(s,2H)、7.3
3(s,5H)、7.74(s,1H) (2)本品3.45g及びシュウ酸0.9gを参考例1
−(2)と同様に処理後、得られる結晶をテトラヒドロ
フラン−イソプロピルエーテル混液から再結晶して、4
−tert−ブトキシカルボニル−5−(2−アミノエ
チル)オキサゾール・1シュウ酸塩2.8gを得る。NMR (CDCl 3 ) δ: 1.58 (s, 9
H), 3.22 to 3.28 (m, 2H), 3.50
3.59 (m, 2H), 5.08 (s, 2H), 7.3
3 (s, 5H), 7.74 (s, 1H) (2) 3.45 g of this product and 0.9 g of oxalic acid were used as Reference Example 1.
-After the same treatment as in (2), the obtained crystals were recrystallized from a tetrahydrofuran-isopropyl ether mixed solution to give 4
2.8 g of -tert-butoxycarbonyl-5- (2-aminoethyl) oxazole.1 oxalate are obtained.
【0120】M.P.116〜120℃M. P. 116-120 ° C
【0121】[0121]
【発明の効果】本発明の有効成分であるジカルボン酸誘
導体〔I〕、そのエステル及びそれらの薬理的に許容し
うる塩は、前記実験例の通り、優れた中性メタロエンド
ペプチダ−ゼ阻害作用を有し、その心房性ナトリウム利
尿ペプチド(ANP)の分解抑制効果にもとづき優れた
利尿作用、Na***促進作用、血管拡張作用、レニン分
泌抑制作用、アルドステロン分泌抑制作用等を示す。こ
のため、本発明の有効成分は、うっ血性心不全、肺、肝
等各種臓器の浮腫、肺水腫、腹水症、胸膜浸出、間質性
腎炎、腎機能不全等の疾患の治療・予防に使用すること
ができる。INDUSTRIAL APPLICABILITY The dicarboxylic acid derivative [I], its ester and the pharmacologically acceptable salt thereof, which are the active ingredients of the present invention, have excellent neutral metalloendopeptidase inhibition as described in the above-mentioned Experimental Examples. It has an action, and exhibits an excellent diuretic action, Na excretion promoting action, vasodilatory action, renin secretion inhibiting action, aldosterone secretion inhibiting action and the like based on its atrial natriuretic peptide (ANP) degradation inhibiting effect. Therefore, the active ingredient of the present invention is used for the treatment / prevention of diseases such as congestive heart failure, edema of various organs such as lung and liver, pulmonary edema, ascites, pleural effusion, interstitial nephritis, renal insufficiency and the like. be able to.
【0122】また、本発明の有効成分は、優れた降圧作
用を示し、本態性高血圧症あるいは二次性高血圧症(腎
性高血圧症、内分泌性高血圧症、心血管性高血圧症、妊
娠に伴う高血圧症、急性ストレスに伴う高血圧症、薬剤
性又はアルコール性その他の高血圧症等)の治療・予防
に用いることができる。特に高血圧症の治療としては、
現在カプトプリル、塩酸デラプリル等のアンギオテンシ
ン変換酵素阻害剤(ACE阻害剤)が臨床的に使用され
ているが、本発明の有効成分であるジカルボン酸誘導体
〔I〕、エステル及びそれらの薬理的に許容し得る塩
は、これらACE阻害剤では比較的効果のない、低レニ
ン性高血圧症にも有効であるという優れた特性を具備す
るものである。Further, the active ingredient of the present invention exhibits an excellent antihypertensive effect and exhibits essential hypertension or secondary hypertension (renal hypertension, endocrine hypertension, cardiovascular hypertension, hypertension associated with pregnancy). , Hypertension associated with acute stress, drug- or alcohol-related hypertension, etc.). Especially for the treatment of hypertension,
Currently, angiotensin converting enzyme inhibitors (ACE inhibitors) such as captopril and delapril hydrochloride are clinically used, but the dicarboxylic acid derivatives [I], esters and their pharmacologically acceptable which are the active ingredients of the present invention are acceptable. The obtained salt has excellent properties that it is relatively ineffective with these ACE inhibitors and is effective for hyporenic hypertension.
【0123】更に、本発明の有効成分は、心筋肥大の抑
制・改善効果をも有し、心筋肥大による心筋収縮力の低
下を防止・改善することができるため、上記で挙げた心
不全、各種浮腫などの他、心不全に伴う肺、肝等の臓器
のうっ血、呼吸困難、全身性浮腫、末梢性チアノーゼ、
夜間発作性呼吸困難、心臓喘息などの症状の治療にも用
いることができる。また浮腫、肺循環不全、高血圧、心
臓弁膜症などの諸症状は心筋肥大を起こして心不全に到
りやすいため、かかる症状を有する患者に対しては、心
不全の予防のために用いることができる。Furthermore, the active ingredient of the present invention also has an effect of suppressing / improving myocardial hypertrophy, and can prevent / improve a decrease in myocardial contractile force due to myocardial hypertrophy. Therefore, the above-mentioned heart failure and various edemas are described. Other than that, congestion of organs such as lungs and liver associated with heart failure, dyspnea, systemic edema, peripheral cyanosis,
It can also be used to treat conditions such as nocturnal paroxysmal dyspnea and cardiac asthma. Further, various symptoms such as edema, pulmonary circulatory insufficiency, hypertension, and valvular heart disease easily cause heart failure due to myocardial hypertrophy. Therefore, it can be used for prevention of heart failure in patients having such symptoms.
【0124】また、本発明の有効成分は、毒性が低く医
薬として安全性が高い。例えば、本発明の有効成分であ
る5−カルボキシ−{2−〔N−((1S)−1−エト
キシカルボニル−3−フェニルプロピル)−(L)−フ
ェニルアラニル〕アミノエチル}オキサゾールを100
0mg/kgの投与量でラットに4週間連続経口投与し
てもラットの死亡例は認められなかった。Further, the active ingredient of the present invention has low toxicity and high safety as a medicine. For example, 5-carboxy- {2- [N-((1S) -1-ethoxycarbonyl-3-phenylpropyl)-(L) -phenylalanyl] aminoethyl} oxazole which is the active ingredient of the present invention is 100
No rat death was observed even when the rats were orally administered at a dose of 0 mg / kg for 4 consecutive weeks.
【0125】なお、既知のANP増強薬には中性メタロ
エンドペプチダーゼ阻害活性と共にアンギオテンシン変
換酵素阻害活性を併有するものもあるが、本発明の有効
成分であるジカルボン酸誘導体〔I〕はアンギオテンシ
ン変換酵素阻害活性が弱く、より選択的な中性メタロエ
ンドペプチダーゼ阻害活性を有するという特長を併せ持
つ。Some known ANP enhancers have both an inhibitory activity against angiotensin converting enzyme in addition to an inhibitory activity against neutral metalloendopeptidase, but the dicarboxylic acid derivative [I] which is the active ingredient of the present invention is an angiotensin converting enzyme. It has weak inhibitory activity and also has the feature of having more selective neutral metalloendopeptidase inhibitory activity.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/42 ABU 7431−4C 31/425 ACX 7431−4C AED 7431−4C C07C 235/34 7106−4H 237/20 7106−4H 321/10 7419−4H C07D 233/64 105 277/28 417/12 9051−4C // C07D 263/32 263/34 (72)発明者 矢野 浩二 東京都保谷市ひばりが丘3丁目5番72− 307 (72)発明者 米田 光 埼玉県大宮市北袋町2−385 田辺製薬大 宮寮─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI Technical display location A61K 31/42 ABU 7431-4C 31/425 ACX 7431-4C AED 7431-4C C07C 235/34 7106- 4H 237/20 7106-4H 321/10 7419-4H C07D 233/64 105 277/28 417/12 9051-4C // C07D 263/32 263/34 (72) Inventor Koji Yano 3 Hibarigaoka, Hoya-shi, Tokyo No. 5 72-307 (72) Inventor Hikaru Yoneda 2-385 Kitabukuro-cho, Omiya-shi, Saitama Tanabe Seiyaku Ohmiya Dormitory
Claims (14)
は水酸基、R1 は炭素数1〜10の直鎖又は分枝鎖アル
キル基、又はアリール基、含硫もしくは含窒素複素単環
式基及び炭素数4〜8のシクロアルキル基から選ばれる
基で置換された低級アルキル基、R2 は置換基を有して
いてもよいアリール基、炭素数4〜8のシクロアルキル
基又は含硫もしくは含窒素複素環式基、Xは硫黄原子、
酸素原子又は置換基を有していてもよいイミノ基、Y1
及びY2 はY1 がイミノ基、酸素原子又は硫黄原子であ
りY2 が窒素原子であるか、又はY1 がビニレン基であ
りY2 が基:−CH=、mは0〜3、nは0又は1を表
す。〕で示されるジカルボン酸誘導体、そのエステル又
はそれらの薬理的に許容しうる塩を有効成分としてなる
中性メタロエンドペプチダーゼ阻害剤。1. A compound represented by the general formula [I]: [Wherein R is a hydrogen atom, a lower alkyl group, a phenyl group or a hydroxyl group, R 1 is a linear or branched alkyl group having 1 to 10 carbon atoms, or an aryl group, a sulfur-containing or nitrogen-containing heteromonocyclic group and A lower alkyl group substituted with a group selected from a cycloalkyl group having 4 to 8 carbon atoms, R 2 is an aryl group which may have a substituent, a cycloalkyl group having 4 to 8 carbon atoms, or a sulfur-containing or sulfur-containing group. Nitrogen heterocyclic group, X is a sulfur atom,
An imino group which may have an oxygen atom or a substituent, Y 1
And Y 2 is Y 1 is an imino group, or is Y 2 is oxygen atom or sulfur atom is a nitrogen atom, or Y 1 is a vinylene group Y 2 is a group: -CH =, m is 0 to 3, n Represents 0 or 1. ] The neutral metallo endopeptidase inhibitor which uses the dicarboxylic acid derivative shown by these, its ester, or those pharmacologically acceptable salt as an active ingredient.
アルキル基、フェニル基置換低級アルキル基、チエニル
基置換低級アルキル基又はシクロヘキシル基置換低級ア
ルキル基、R2 がフェニル基、低級アルコキシ基置換フ
ェニル基、シクロヘキシル基、チエニル基又はインドリ
ル基、Xが硫黄原子、イミノ基又は低級アルキル基置換
イミノ基である請求項1記載の中性メタロエンドペプチ
ダーゼ阻害剤。2. R 1 is a linear or branched alkyl group having 1 to 10 carbon atoms, a phenyl group-substituted lower alkyl group, a thienyl group-substituted lower alkyl group or a cyclohexyl group-substituted lower alkyl group, and R 2 is a phenyl group, The neutral metalloendopeptidase inhibitor according to claim 1, wherein a lower alkoxy group-substituted phenyl group, a cyclohexyl group, a thienyl group or an indolyl group, and X is a sulfur atom, an imino group or a lower alkyl group-substituted imino group.
換フェニル基、チエニル基又はインドリル基である請求
項2記載の中性メタロエンドペプチダーゼ阻害剤。3. The neutral metalloendopeptidase inhibitor according to claim 2, wherein R 2 is a phenyl group, a lower alkoxy group-substituted phenyl group, a thienyl group or an indolyl group.
アルキル基、フェニル基置換低級アルキル基又はチエニ
ル基置換低級アルキル基、R2 がフェニル基又は低級ア
ルコキシ基置換フェニル基、Xがイミノ基又は低級アル
キル基置換イミノ基、Y1 がイミノ基、酸素原子又は硫
黄原子、Y2 が窒素原子、mが2、nが0である請求項
3記載の中性メタロエンドペプチダーゼ阻害剤。Wherein R 1 is a linear or branched alkyl group having 1 to 10 carbon atoms, a phenyl-substituted lower alkyl group or thienyl group substituted lower alkyl group, R 2 is a phenyl group or a lower alkoxy-substituted phenyl group, The neutral metalloendopeptidase inhibitor according to claim 3, wherein X is an imino group or a lower alkyl group-substituted imino group, Y 1 is an imino group, an oxygen atom or a sulfur atom, Y 2 is a nitrogen atom, m is 2 and n is 0. Agent.
直鎖又は分枝鎖アルキル基又はフェニル基置換低級アル
キル基、R2 がフェニル基、Xがイミノ基、Y1 が酸素
原子又は硫黄原子、Y2 が窒素原子である請求項4記載
の中性メタロエンドペプチダーゼ阻害剤。5. R is a hydrogen atom, R 1 is a linear or branched alkyl group having 1 to 10 carbon atoms or a phenyl group-substituted lower alkyl group, R 2 is a phenyl group, X is an imino group, and Y 1 is oxygen. The neutral metalloendopeptidase inhibitor according to claim 4, wherein the atom or sulfur atom and Y 2 are nitrogen atoms.
は水酸基、R1 がsec−ブチル基、sec−ペンチル
基、n−オクチル基、ベンジル基、フェニルエチル基、
チエニルエチル基又はシクロヘキシルエチル基、R2 が
フェニル基、メトキシフェニル基、チエニル基又はイン
ドリル基、Xが硫黄原子、イミノ基又はメチルイミノ基
である請求項3記載の中性メタロエンドペプチダーゼ阻
害剤。6. R is hydrogen atom, methyl group, phenyl group or hydroxyl group, R 1 is sec-butyl group, sec-pentyl group, n-octyl group, benzyl group, phenylethyl group,
The neutral metalloendopeptidase inhibitor according to claim 3, wherein R 2 is a phenyl group, a methoxyphenyl group, a thienyl group or an indolyl group, and X is a sulfur atom, an imino group or a methylimino group.
基、R1 がn−オクチル基、フェニルエチル基又はチエ
ニルエチル基、R2 がフェニル基又はメトキシフェニル
基、Xがイミノ基又はメチルイミノ基である請求項6記
載の中性メタロエンドペプチダーゼ阻害剤。7. R is a hydrogen atom, a methyl group or a phenyl group, R 1 is an n-octyl group, a phenylethyl group or a thienylethyl group, R 2 is a phenyl group or a methoxyphenyl group, and X is an imino group or a methylimino group. The neutral metalloendopeptidase inhibitor according to claim 6.
はフェニルエチル基、R2 がフェニル基、Xがイミノ
基、Y1 が酸素原子又は硫黄原子、Y2 が窒素原子であ
る請求項7記載の中性メタロエンドペプチダーゼ阻害
剤。8. A hydrogen atom, R 1 is an n-octyl group or a phenylethyl group, R 2 is a phenyl group, X is an imino group, Y 1 is an oxygen atom or a sulfur atom, and Y 2 is a nitrogen atom. Item 9. The neutral metalloendopeptidase inhibitor according to Item 7.
直鎖又は分子鎖アルキルエステル又はフェニル低級アル
キルエステルである請求項1〜8記載の中性メタロエン
ドペプチダーゼ阻害剤。9. The neutral metalloendopeptidase inhibitor according to claim 1, which is a linear or molecular chain alkyl ester having 1 to 10 carbon atoms or a phenyl lower alkyl ester of a dicarboxylic acid derivative.
である請求項9記載の中性メタロエンドペプチダーゼ阻
害剤。10. The neutral metalloendopeptidase inhibitor according to claim 9, which is a mono- or di-lower alkyl ester.
対配置をとる請求項1〜10記載の中性メタロエンドペ
プチダーゼ阻害剤。11. The neutral metalloendopeptidase inhibitor according to claim 1, wherein the two asymmetric carbon atoms each have an absolute configuration of S configuration.
((1S)−1−カルボキシ−3−フェニルプロピル)
−(L)−フェニルアラニル〕アミノエチル}チアゾー
ル、そのエステル又はその薬理的に許容しうる塩を有効
成分としてなる中性メタロエンドペプチダーゼ阻害剤。12. 4-carboxy-5- {2- [N-
((1S) -1-carboxy-3-phenylpropyl)
A neutral metalloendopeptidase inhibitor comprising-(L) -phenylalanyl] aminoethyl} thiazole, its ester or a pharmacologically acceptable salt thereof as an active ingredient.
((1S)−1−カルボキシ−3−フェニルプロピル)
−(L)−フェニルアラニル〕アミノエチル}オキサゾ
ール、そのエステル又はその薬理的に許容しうる塩を有
効成分としてなる中性メタロエンドペプチダーゼ阻害
剤。13. 4-carboxy-5- {2- [N-
((1S) -1-carboxy-3-phenylpropyl)
A neutral metalloendopeptidase inhibitor comprising-(L) -phenylalanyl] aminoethyl} oxazole, an ester thereof, or a pharmacologically acceptable salt thereof as an active ingredient.
防・治療剤である請求項1〜13記載の中性メタロエン
ドペプチダーゼ阻害剤。14. The neutral metalloendopeptidase inhibitor according to claim 1, which is a hypotensive agent, a diuretic agent, and / or a prophylactic / therapeutic agent for heart failure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5312366A JPH06234630A (en) | 1992-12-17 | 1993-12-14 | Neutral metalloendopeptidase inhibitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4-337095 | 1992-12-17 | ||
JP33709592 | 1992-12-17 | ||
JP5312366A JPH06234630A (en) | 1992-12-17 | 1993-12-14 | Neutral metalloendopeptidase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06234630A true JPH06234630A (en) | 1994-08-23 |
Family
ID=26567142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5312366A Pending JPH06234630A (en) | 1992-12-17 | 1993-12-14 | Neutral metalloendopeptidase inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH06234630A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019466A1 (en) * | 1994-12-21 | 1996-06-27 | Eli Lilly And Company | Process for preparing benzyl-substituted rhodanine derivatives |
US8222286B2 (en) | 2009-11-20 | 2012-07-17 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8263629B2 (en) | 2009-05-28 | 2012-09-11 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8394853B2 (en) | 2009-05-28 | 2013-03-12 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
-
1993
- 1993-12-14 JP JP5312366A patent/JPH06234630A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996019466A1 (en) * | 1994-12-21 | 1996-06-27 | Eli Lilly And Company | Process for preparing benzyl-substituted rhodanine derivatives |
US8263629B2 (en) | 2009-05-28 | 2012-09-11 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8394853B2 (en) | 2009-05-28 | 2013-03-12 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
US9006249B2 (en) | 2009-05-28 | 2015-04-14 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US9603819B2 (en) | 2009-05-28 | 2017-03-28 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8222286B2 (en) | 2009-11-20 | 2012-07-17 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8377978B2 (en) | 2009-11-20 | 2013-02-19 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8642635B2 (en) | 2009-11-20 | 2014-02-04 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8877786B2 (en) | 2009-11-20 | 2014-11-04 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5801274A (en) | N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives | |
US4425333A (en) | Sulfur-containing acylamino acids | |
AU691243B2 (en) | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace | |
EP0082088A1 (en) | Derivatives of amino acids and their therapeutic use | |
JPH09505601A (en) | Indolyl-containing compounds and their use to promote growth hormone release | |
MXPA98001093A (en) | Inhibitors of proteinase c for the treatment of diseases related to the overproduction of colag | |
EP0236734A2 (en) | 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups | |
FR2778406A1 (en) | Alpha-cetoamides for treating viral infections especially hepatitis C, hepatitis G and human GB | |
WO1996016079A2 (en) | Alpha-ketoamide derivatives as cathepsin l inhibitor | |
US5523313A (en) | Indole-containing peptide and process for preparing the same | |
EP0655461A1 (en) | Cyclic amino acid derivatives having ACE and NEP inhibiting activity | |
TW200407310A (en) | Compounds | |
US5312826A (en) | N,3-disubstituted alaninamide derivatives | |
EP0262053A2 (en) | Amino-acid derivatives, their preparation and pharmaceutical compositions containing them | |
JPH06234630A (en) | Neutral metalloendopeptidase inhibitor | |
EP1140981B1 (en) | Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions | |
JPH06500326A (en) | N-(mercaptoalkyl)ureas and carbamates | |
IE922214A1 (en) | Pharmaceutical composition | |
FR2532308A1 (en) | NOVEL POLYPEPTIDES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES | |
EP0723974B1 (en) | Derivatives of mercaptoalkanoyldipeptides, their preparation and pharmaceutical compositions containing them | |
JP2002505320A (en) | Matrix metalloproteinase inhibitors | |
JPH08208462A (en) | Cathepsin l inhibitor | |
JPH0867632A (en) | Neutral metalloendopeptidase-inhibiting agent | |
IE65539B1 (en) | Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same | |
JPH05208964A (en) | Dicarboxylic acid and its production |